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Disclosure of Relationships
The 2016–2017 ACIP Hepatitis Vaccines Work Group 
members wish to disclose that they have no financial or 
competing interests with the manufacturers of commercial 
products or suppliers of commercial services related to 
hepatitis B (HepB) vaccines. Content will not include any 
discussion of the unlabeled use of a product or a product under 
investigational use, with the following exceptions:
• use of Pediarix vaccine for infants born to hepatitis B 
surface antigen (HBsAg)–positive mothers or mothers 
with an unknown HBsAg status to complete the vaccine 
series after receipt of a birth dose of single-antigen HepB 
vaccine and hepatitis B immune globulin (HBIG);
• alternate 3-dose vaccine administration schedules heeding 
to minimum intervals of 4 weeks between the first and 
second dose, 8 weeks between the second and third dose, 
and 16 weeks between the first and third dose;
• modified dosing regimens (e.g., doubling of standard dose 
and administration of additional doses) in certain 
circumstances (e.g., for persons with immunocompromising 
conditions); and
• antiviral therapy during pregnancy for the prevention of 
perinatal hepatitis B virus (HBV) transmission.
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Summary
Hepatitis B virus (HBV) is transmitted via blood or sexual contact. Persons with chronic HBV infection are at increased risk for 
cirrhosis and liver cancer and require medical care. This report updates and summarizes previously published recommendations 
from the Advisory Committee on Immunization Practices (ACIP) and CDC regarding the prevention of HBV infection in the 
United States. ACIP recommends testing all pregnant women for hepatitis B surface antigen (HBsAg), and testing HBsAg-positive 
pregnant women for hepatitis B virus deoxyribonucleic acid (HBV DNA); administration of HepB vaccine and hepatitis B immune 
globulin (HBIG) for infants born to HBV-infected women within 12 hours of birth, followed by completion of the vaccine series and 
postvaccination serologic testing; universal hepatitis B vaccination within 24 hours of birth, followed by completion of the vaccine 
series; and vaccination of children and adolescents aged <19 years who have not been vaccinated previously. ACIP recommends 
vaccination of adults at risk for HBV infection, including universal vaccination of adults in settings in which a high proportion 
have risk factors for HBV infection and vaccination of adults requesting protection from HBV without acknowledgment of a 
specific risk factor. These recommendations also provide CDC guidance for postexposure prophylaxis following occupational and 
other exposures. This report also briefly summarizes previously published American Association for the Study of Liver Diseases 
guidelines for maternal antiviral therapy to reduce perinatal HBV transmission.
Introduction
Hepatitis B virus (HBV) is transmitted through percutaneous 
(i.e., puncture through the skin) or mucosal (i.e., direct contact 
with mucous membranes) exposure to infectious blood or 
body fluids. HBV is highly infectious, can be transmitted 
in the absence of visible blood (1,2), and remains viable on 
environmental surfaces for at least seven days (3). Persons 
with chronic infection (e.g., those with persistent hepatitis B 
surface antigen [HBsAg] in the serum for at least 6 months 
following acute infection) serve as the main reservoir for HBV 
transmission (4).
This report summarizes and consolidates previously 
published recommendations from the Advisory Committee 
on Immunization Practices (ACIP) and CDC. It also 
Corresponding author: Sarah Schillie, Division of Viral Hepatitis, 
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB 
Prevention, CDC. Telephone: 404-718-8608; E-mail: Ggi1@cdc.gov.
contains updates to recommendations for the prevention of 
HBV infection in the United States. A list of frequently used 
abbreviations is provided (Box 1).
New or Updated Recommendations
The following recommendations are new or updated:
• universal hepatitis B (HepB) vaccination within 
24 hours of birth for medically stable infants weighing 
≥2,000 grams;
• testing HBsAg-positive pregnant women for hepatitis B 
virus deoxyribonucleic acid (HBV DNA);
• postvaccination serologic testing for infants whose 
mother’s HBsAg status remains unknown indefinitely (e.g., 
when a parent or person with lawful custody surrenders 
an infant confidentially shortly after birth);
• single-dose revaccination for infants born to HBsAg-
positive women not responding to the initial vaccine series;
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• vaccination for persons with chronic liver disease (including, 
but not limited to, those with hepatitis C virus [HCV] 
infection, cirrhosis, fatty liver disease, alcoholic liver disease, 
autoimmune hepatitis, and an alanine aminotransferase 
[ALT] or aspartate aminotransferase [AST] level greater than 
twice the upper limit of normal); and
• removal of permissive language for delaying the birth dose 
until after hospital discharge.
This report also briefly summarizes American Association for 
the Study of Liver Diseases (AASLD) guidelines for maternal 
antiviral therapy to reduce perinatal HBV transmission, 
published previously (5). Recommendations from the 
Infectious Diseases Society of America (IDSA) regarding 
vaccination of the immunocompromised host are published 
separately (6).
Methods
ACIP’s Hepatitis Work Group comprises professionals 
from academic medicine (pediatrics, family medicine, 
internal medicine, infectious disease, occupational health, 
and preventive medicine specialists), federal and state public 
health agencies, and medical societies.* The Work Group 
reviewed epidemiology and literature, directed an economic 
analysis, and deliberated upon recommendations. The 
Work Group considered existing published ACIP and CDC 
vaccine recommendations in summarizing recommendations 
contained herein for the prevention of HBV infection.
This report updates and supplants ACIP recommendations 
for HepB vaccination of children and adults published 
previously (7,8). This report incorporates ACIP and CDC 
recommendations published previously (9–11).
Guidelines from AASLD inform the use of antiviral 
therapy among pregnant women with elevated HBV DNA 
for the purpose of preventing perinatal HBV transmission. 
Surveillance data were obtained from the National Notifiable 
Diseases Surveillance System (NNDSS) (https://wwwn.cdc.
gov/nndss/).
Data informing clarifications to the recommendations were 
summarized on the basis of findings from literature searches 
that were completed on May 11, 2016. Two search terms were 
used to ascertain data regarding maximum number of doses 
for dialysis patients and minimum intervals for dialysis dosing: 
“Hepatitis b vacc* dialysis boost*” and “Dialysis hepatitis b 
vacc* schedule.” Epidemiologic and vaccine coverage data were 
reviewed, as well as publicly available data on the number 
of infant abandonments and safely surrendered infants. The 
literature searches included clinical trials and comparative 
* A list of the members appears on page 30.
BOX 1. Abbreviations used in this report
AASLD  American Association for the Study of 
Liver Diseases
ACIP  Advisory Committee on Immunization 
Practices
anti-HBc  antibody to hepatitis B core antigen
anti-HBe  antibody to hepatitis B e antigen
anti-HBs  antibody to hepatitis B surface antigen
HBeAg  hepatitis B e antigen
HBIG  hepatitis B immune globulin
HBsAg  hepatitis B surface antigen
HBV  hepatitis B virus
HBV DNA hepatitis B virus deoxyribonucleic acid
HCP  health care personnel
HCV  hepatitis C virus
HepB  hepatitis B 
HIV  human immunodeficiency virus
IDSA  Infectious Diseases Society of America
IDU  Injection-drug use
IgM  Immunoglobulin class M
IgG  Immunoglobulin class G
MSM  men who have sex with men
NNDSS  National Notifiable Diseases Surveillance 
System
PHBPP  Perinatal Hepatitis B Prevention Program
PWID  persons who inject drugs
QALY  quality-adjusted life-year
STI  sexually transmitted infection
VAERS  Vaccine Adverse Events Reporting System
VSD  Vaccine Safety Datalink
studies conducted worldwide and published in English since 
2000. All studies yielding pertinent information were eligible 
for inclusion. Search results were supplemented by additional 
relevant papers identified by subject matter experts on the 
Work Group. Per the ACIP process, it was predetermined that 
Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) was not required for these updates of 
existing recommendations.
To assess vaccine safety, the Work Group searched two 
postlicensure surveillance systems for adverse events from 
2005 through 2015: the Vaccine Adverse Events Reporting 
System (VAERS) (https://vaers.hhs.gov) and the Vaccine 
Safety Datalink (VSD) (https://www.cdc.gov/vaccinesafety/
ensuringsafety/monitoring/vsd). VAERS is a national passive 
surveillance system, and VSD conducts population-based 
vaccine safety studies. VAERS can generate vaccine safety 
hypotheses but cannot assess causality and is subject to several 
limitations, including reporting biases and inconsistent data 
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quality (12,13). VSD can be used to assess hypotheses that 
arise from reviews of medical literature, reports to VAERS, 
changes in immunization schedules, or the introduction of 
new vaccines (14).
During February–September 2016, the Work Group held 
five teleconference meetings. Work Group and ACIP members 
also reviewed and commented on a draft of the statement prior 
to the ACIP’s October 2016 meeting. A summary of Work 
Group discussions was presented to ACIP on October 19, 2016. 
At that time, ACIP members voted to approve a draft HepB 
vaccine recommendations statement, including recommending 
universal HepB vaccination within 24 hours of birth for 
medically stable infants weighing ≥2,000 grams. In January 
2017, the Work Group held a teleconference meeting to review 
results of an economic analysis of single-dose revaccination 
for infants born to HBsAg-positive women. Results from 
that analysis were presented to ACIP on February 22, 2017. 
Recommendations were not evaluated using GRADE, but 
expert opinion was used to shape the recommendations. At 
that time, ACIP members voted to approve language for single-
dose revaccination for infants (regardless of birth weight) born 
to HBsAg-positive women. Modifications were made to the 
ACIP statement during the subsequent review process at CDC 
to update and clarify wording in the report.
HBV Background
Epidemiology
In 2015, a total of 3,370 cases of acute HBV infection 
were reported to CDC. The actual number of acute cases is 
believed to be 6.5 times the number of reported cases in any 
year. It is estimated that 21,900 new cases of HBV occurred 
in 2015 after under-ascertainment and under-reporting were 
considered (4). The rate of reported acute HBV infections 
declined 88.5% since recommendations for HepB vaccination 
were first issued, from 9.6 cases per 100,000 population 
in 1982 to 1.1 cases per 100,000 population in 2015 (15), 
although the rate of acute HBV infections remained fairly 
stable during 2010–2015 (4) (Figure 1). The 2015 incidence 
is greatest for persons aged 30–39 years (2.6 per 100,000 
population). In 2015, persons aged ≤19 years had the lowest 
incidence (0.02 cases per 100,000 population), likely a result 
of routine infant vaccination. Although the incidence of acute 
HBV infection is greater for males than for females, the gap 
has narrowed; in 2015, the rate for males was approximately 
1.6 times higher than that for females (1.3 cases and 0.8 cases 
per 100,000 population, respectively) (4). During 2009–2013, 
the combined incidence of acute HBV infection in three states 
(Kentucky, Tennessee, and West Virginia) increased 114% and 
was associated with increasing injection-drug use (16).
On the basis of national health survey data, it is estimated 
that approximately 850,000 persons are living with HBV 
infection (prevalence) in the United States (17,18). Studies 
based on data from countries of persons migrating to the 
United States and census data indicate that the total prevalence 
of chronic hepatitis B might be as high as 2.2 million persons 
(19), suggesting that the national health survey-based estimate 
might be conservative. Foreign-born persons account for 
approximately 95% of newly reported chronic infections in the 
United States (20); the prevalence of chronic HBV infection 
is approximately 3.5% among foreign-born persons (19), and 
the majority of chronic HBV infections in the United States 
are among Asians/Pacific Islanders.
Strategy to Eliminate HBV
In 1991, the United States adopted a strategy for universal 
HepB vaccination of infants (21). A comprehensive strategy 
to eliminate HBV transmission evolved over the ensuing three 
decades and encompasses 1) routine testing of all pregnant 
women for HBsAg and prophylaxis for infants born to HBsAg-
positive mothers, 2) universal vaccination of infants beginning at 
birth, 3) routine vaccination of previously unvaccinated children 
and adolescents, and 4) vaccination of adults at risk for HBV 
infection (7–11,21–26). Preventing perinatal transmission relies 
upon testing all pregnant women for HBsAg and administering 
timely prophylaxis (HepB vaccine and hepatitis B immune 
globulin [HBIG]) to infants born to infected mothers. Universal 
HepB vaccination of all infants beginning at birth provides a 
critical safeguard and prevents infection among infants born 
to HBsAg-positive mothers not identified prenatally (e.g., in 
situations where the mother was not tested or when testing, 
interpretation, or transcription errors occurred). Vaccination 
of children and adolescents not previously vaccinated and 
vaccination of adults at risk for HBV infection (e.g., by sexual 
or percutaneous exposure and international travelers to certain 
countries) is recommended to prevent HBV transmission outside 
of the perinatal setting (Box 2).
HBV prevention strategies have been implemented 
successfully in the United States, but challenges remain. 
Approximately 88% of commercially insured women and 
84% of Medicaid-enrolled women are tested for HBsAg 
during pregnancy (27). In one study of a large health system 
in northern California, 93% of HBsAg-positive pregnant 
women were tested for HBV DNA (28). Most (94.9%) infants 
born to infected women receive recommended prophylaxis 
within 12 hours of birth (29). Universal HepB vaccine birth 
dose coverage, defined as 1 dose of vaccine administered 
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FIGURE 1. Incidence of hepatitis B virus infection — National Notifiable Diseases Surveillance System, United States, 1980–2015
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by 3 days of life, is 71.1% (30), an increase from 50.1% 
during 2003–2005 prior to revised ACIP recommendations 
for the birth dose before hospital discharge (31), but below 
the Healthy People 2020 target of 85% (32). HepB vaccine 
coverage (≥3 doses) among children aged 19–35 months and 
13–17 years is 90.5% (30) and 91.4% (33), respectively. 
Vaccine coverage (≥3 doses) is lower among adults: 27.4% 
among adults who report chronic liver conditions; 31.6% 
among adults who traveled outside the United States to 
countries other than Europe, Japan, Australia, New Zealand, 
or Canada since 1995; and 24.4% among adults with 
diabetes aged 19–59 years and 12.6% of adults with diabetes 
aged ≥60 years (34). Among health care personnel (HCP), 
≥3-dose coverage was 64.7%, an increase from 51% in 1992 
shortly after implementation of the Needlestick Safety and 
Prevention Act (35), but well below the Healthy People 2020 
target of 90% (32,34).
New strategies for further reducing HBV transmission in 
this report include testing HBsAg-positive pregnant women 
for HBV DNA to identify infants at greatest risk for infection 
and guide the use of maternal antiviral therapy (36,37). 
Published evidence indicates that maternal antiviral therapy 
during pregnancy further reduces perinatal HBV transmission; 
hence, AASLD suggests antiviral therapy when maternal HBV 
DNA is >200,000 IU/mL (5,38,39).
Virus Description and Transmission
HBV is a 40–42-nm enveloped virus classified in the 
Hepadnaviridae family. HBV contains a circular, partially 
double-stranded DNA genome that is 3.2 kb in length. After 
a susceptible person is exposed, the virus enters the liver 
via the bloodstream. The liver is the primary site of HBV 
replication (40–43).
HBV has been classified by two separate systems: serologic 
subtype and genotype. Nine serologic subtypes initially were 
described based on the heterogeneity of HBsAg: adrq+, adrq–, 
ayr, ayw1, ayw2, ayw3, ayw4, adw2, and adw4 (44,45). Ten 
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HBV genotypes, designated A–J, have been described. HBV 
serotypes and genotypes vary geographically. Infection or 
immunization with one genotype generally confers immunity 
to all genotypes (7,44,46,47).
HBV is highly infectious, can be transmitted in the absence 
of visible blood (22), and remains infectious on environmental 
surfaces for at least 7 days (2,3). All HBsAg-positive persons are 
infectious, but those with elevated HBV DNA or those with 
hepatitis B e antigen (HBeAg), a protein from the hepatitis B 
virus that circulates in the blood and is a marker of infectivity, 
are most infectious. Persons with occult HBV infection (i.e., 
those who test negative for HBsAg but have detectable HBV 
DNA) also might transmit infection (48).
HBV is transmitted through percutaneous, mucosal, 
or nonintact skin exposure to infectious blood or body 
fluids. HBV is concentrated most highly in blood, and 
percutaneous exposure is an efficient mode of transmission. 
Semen and vaginal secretions are infectious, and HBV also 
can be detected in saliva, tears, and bile. Cerebrospinal fluid, 
synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid, 
and amniotic fluid are also considered potentially infectious. 
Urine, feces, vomitus, nasopharyngeal washings, sputum, 
and sweat are not efficient vehicles of transmission unless 
they contain blood because they contain low quantities of 
infectious HBV. HBsAg found in breast milk is also unlikely 
to lead to transmission, and hence HBV infection is not a 
contraindication to breastfeeding (2,7,22).
Among adults, HBV is transmitted primarily by percutaneous 
exposure to blood (e.g., by injection-drug use) and sexual 
contact. HBV is transmitted efficiently by sexual contact 
both among heterosexuals and among men who have sex 
with men (MSM). Risk factors for sexual transmission among 
heterosexuals include having unprotected sex with an infected 
partner, having unprotected sex with more than one partner, 
and a history of another sexually transmitted infection (STI). 
Risk factors associated with sexual transmission among MSM 
include having multiple sex partners, history of another 
STI, and anal intercourse. Transmission can occur from 
interpersonal contact (e.g., sharing a toothbrush or razor, 
contact with exudates from dermatologic lesions, or contact 
with HBsAg-contaminated surfaces) and in settings such as 
schools, child care centers, and facilities for developmentally 
disabled persons. Transmission of HBV from transfusion of 
blood or blood products is rare because of donor screening 
and viral inactivation procedures. Other possible sources of 
infection include contaminated medical or dental instruments, 
unsafe injections, needle-stick injuries, organ transplantation, 
and dialysis (49).
BOX 2. Strategy to eliminate HBV transmission in the United States*
• Screening of all pregnant women for HBsAg
 – HBV DNA testing for HBsAg-positive pregnant 
women, with suggestion of maternal antiviral 
therapy to reduce perinatal transmission when 
HBV DNA is >200,000 IU/mL
 – Prophylaxis (HepB vaccine and HBIG) for infants 
born to HBsAg-positive† women
• Universal vaccination of all infants beginning at 
birth§,¶ as a safeguard for infants born to HBV-
infected mothers not identified prenatally
• Routine vaccination of previously unvaccinated 
children aged <19 years
• Vaccination of adults at risk for HBV infection, 
including those requesting protection from HBV 
without acknowledgment of a specific risk factor
* Sources: Mast EE, Margolis HS, Fiore AE, et al. A comprehensive 
immunization strategy to eliminate transmission of hepatitis B virus 
infection in the United States: recommendations of the Advisory 
Committee on Immunization Practices (ACIP). Part 1: immunization of 
infants, children, and adolescents. MMWR Recomm Rep 2005;54(No. 
RR-16):1–31; Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive 
immunization strategy to eliminate transmission of hepatitis B virus 
infection in the United States: recommendations of the Advisory 
Committee on Immunization Practices (ACIP). Part II: immunization 
of adults. MMWR Recomm Rep 2006;55(No. RR-16):1–33.
† Refer to Table 3 for prophylaxis recommendations for infants born to 
women with unknown HBsAg status.
§ Within 24 hours of birth for medically stable infants weighing ≥2,000 grams.
¶ Refer to Table 3 for birth dose recommendations for infants weighing 
<2,000 grams.
Clinical Features and Natural History
Clinical manifestations of HBV infection range from 
asymptomatic infection to fulminant hepatitis. The average 
incubation period is 60 days (range: 40–90 days) from exposure 
to onset of abnormal serum ALT levels and 90 days (range: 
60–150 days) from exposure to onset of jaundice (8,42,43). 
Infants, children aged <5 years, and immunosuppressed adults 
with newly acquired HBV infection typically are asymptomatic, 
whereas symptomatic illness is noted in 30%–50% of older 
children, adolescents, and adults (7,8,44,50). When present, 
signs and symptoms include nausea, vomiting, abdominal 
pain, fever, dark urine, changes in stool color, hepatomegaly, 
splenomegaly, and jaundice. Malaise and anorexia might 
precede jaundice by 1–2 weeks. Fulminant HBV infection is 
uncommon (<1%) but often results in death or liver failure 
necessitating liver transplantation. Extrahepatic manifestations 
of disease (e.g., skin rash, arthralgias, and arthritis) also might 
occur (51). The fatality rate among persons with reported 
cases of acute HBV infection is <1.5%, with the highest rates 
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in adults aged ≥55 years. Because a substantial number of 
infections are asymptomatic and therefore are not reported, 
the overall fatality rate among all persons with HBV infection 
is likely lower (8).
Chronic infection occurs among 80%–90% of persons 
infected during infancy, 30% of persons infected before 
age 6 years, and <1%–12% of persons infected as an older 
child or adult (7,52–54). Approximately 95% of primary 
infections in immunocompetent adults are self-limited, with 
elimination of the virus from blood and generally immunity 
to reinfection. Chronic infection develops more frequently 
in immunosuppressed persons (e.g., hemodialysis patients 
and persons with human immunodeficiency virus [HIV] 
infection) (54,55) and persons with diabetes (54). Chronic 
HBV infection can result in cirrhosis of the liver, liver cancer, 
liver failure, and death. Approximately 25% of persons who 
become chronically infected during childhood and 15% of 
those who become chronically infected after childhood will 
die prematurely from cirrhosis or liver cancer (8,56–58).
There are four phases of chronic HBV infection: immune 
tolerant, immune active, immune inactive, and reactivation. 
Chronically infected persons do not necessarily pass through 
these phases in a linear fashion. Persons in the immune 
tolerant phase have no or minimal hepatic inflammation or 
fibrosis; most chronically infected children will remain in the 
immune tolerant phase until late childhood or adolescence. 
The immune active phase is characterized by an active immune 
response resulting in hepatic inflammation, with or without 
fibrosis. Persons who remain in the immune active phase 
for prolonged periods of time are at high risk for developing 
cirrhosis and hepatocellular carcinoma. Persons in the immune 
inactive phase have improvement of hepatic inflammation and 
fibrosis. Risk for progression to hepatocellular carcinoma is 
lower among persons in the immune inactive phase compared 
with the active phase. Persons in the reactivation phase have 
active liver inflammation with or without fibrosis (44,59–61). 
HBV reactivation might occur with immunosuppressive 
therapy or treatment for HCV (62).
No specific treatment exists for acute HBV infection; 
supportive care is the mainstay of therapy. Guidelines for 
management of chronic HBV infection in children and adults, 
including disease monitoring and antiviral therapy, are available 
(5). Antiviral therapy generally should be initiated in patients 
with chronic HBV infection who are likely to respond to 
treatment and who are at high risk for liver-related morbidity 
(5). Maternal antiviral therapy to reduce perinatal transmission 
is suggested for HBsAg-positive pregnant women whose HBV 
DNA level is >200,000 IU/mL (5).
In areas in which HBV is highly endemic, HBV frequently 
is transmitted perinatally from HBV-infected pregnant women 
to their newborns. The majority of cases of perinatal HBV 
transmission occur during delivery, with rare instances of in 
utero transmission (63). HBV transmission might occur in germ 
cell lines, as the virus has been detected in sperm, oocytes, and 
embryos. Available data do not support the need for a cesarean 
delivery among HBV-infected pregnant women with low HBV 
DNA (63). Prior to the widespread availability of postexposure 
prophylaxis, the proportion of infants born to HBsAg-positive 
women acquiring HBV infection was approximately 30% for 
those born to HBeAg-negative mothers and 85% for those born 
to HBeAg-positive mothers. With postexposure prophylaxis, 
comprised of HepB vaccine and HBIG at birth, followed by 
completion of the HepB vaccine series, 0.7%–1.1% of infants 
develop infection (28,29,64); infants born to mothers with high 
viral loads are at greatest risk for infection despite receipt of HepB 
vaccine and HBIG (29). Unvaccinated infants and children are 
also at risk for horizontal transmission from infected household 
and other contacts.
Interpretation of Serologic Markers
Serologic markers for HBV infection include HBsAg, 
antibody to HBsAg (anti-HBs), immunoglobulin class M 
(IgM) antibodies to hepatitis B core antigen (IgM anti-HBc), 
and immunoglobulin class G (IgG) anti-HBc (IgG anti-HBc) 
(49,65,66). At least one serologic marker is present during 
the different phases of infection. HBV DNA is a measure 
of viral load and reflects viral replication (49) (Table 1). 
Hepatitis B e antigen (HBeAg) can be detected in persons 
with acute or chronic HBV infection; the presence of HBeAg 
correlates with viral replication and high infectivity; antibody 
to HBeAg (anti-HBe) correlates with the loss of replicating 
virus, although reversion to HBeAg positivity can occur (7).
A confirmed positive HBsAg result indicates current HBV 
infection, either acute or chronic. All HBsAg-positive persons are 
infectious. If HBsAg persists for >6 months, spontaneous clearance 
is unlikely, and the infection is deemed chronic. HBV DNA can 
be detected prior to the detection of HBsAg in an infected person. 
Occult infection occurs when HBsAg is undetectable despite the 
presence of HBV DNA (66–68). Transient HBsAg positivity can 
occur up to 18 days following vaccination (up to 52 days among 
hemodialysis patients) and is clinically insignificant (69).
In acute HBV infection, anti-HBc (initially both IgM and 
IgG) appears 1–2 weeks after the appearance of HBsAg (49) 
(Figure 2). IgM anti-HBc often becomes undetectable within 
6 months, and IgG anti-HBc predominates and remains 
detectable for a lengthy period of time, often life-long (65,66). 
The presence of IgM anti-HBc is indicative of acute infection, 
while IgG anti-HBc indicates past infection (65,66). In persons 
who recover from HBV infection, HBsAg is eliminated from 
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TABLE 1. Typical interpretation of test results for hepatitis B virus infection
HBsAg Total anti-HBc IgM anti-HBc Anti-HBs HBV DNA Interpretation
- - - - - Never infected
+ - - - + or - Early acute infection; transient (up to 18 days) after vaccination
+ + + - + Acute infection
- + + + or - + or - Acute resolving infection
- + - + - Recovered from past infection and immune
+ + - - + Chronic infection
- + - - + or - False-positive (i.e., susceptible); past infection; “low-level” chronic infection; or passive 
transfer of anti-HBc to infant born to HBsAg-positive mother
- - - + - Immune if anti-HBs concentration is ≥10 mIU/mL after vaccine series completion; 
passive transfer after hepatitis B immune globulin administration
Abbreviations: - = negative; + = positive; anti-HBc = antibody to hepatitis B core antigen; anti-HBs = antibody to hepatitis B surface antigen; HBsAg = hepatitis B 
surface antigen; HBV DNA = hepatitis B virus deoxyribonucleic acid; IgM = immunoglobulin class M.
the blood and anti-HBs develops, typically within 3–4 months. 
The presence of anti-HBs is generally indicative of immunity 
to HBV infection (8). Anti-HBs also can be detected for 4–6 
months following HBIG administration (10). Persons who 
recover from natural HBV infection are typically positive for 
both anti-HBs and anti-HBc, whereas persons who respond to 
HepB vaccine are positive only for anti-HBs. Approximately 
0.5%–2% of persons with chronic infection spontaneously 
clear HBsAg yearly; anti-HBs will develop in the majority of 
these persons (8).
In certain persons, anti-HBc is the only serologic marker 
detected. Isolated anti-HBc-positivity can be detected 
following HBV infection in persons who have recovered but 
whose anti-HBs levels have waned; in populations with a 
high prevalence of HBV infection, isolated anti-HBc likely 
indicates previous infection with loss of anti-HBs. Some 
chronically infected persons with isolated anti-HBc-positivity 
have circulating HBsAg that is not detectable by a laboratory 
assay. HBV DNA has been detected in <10% of persons with 
isolated anti-HBc (70,71), although the presence of detectable 
HBV DNA might fluctuate (72). These persons are unlikely to 
transmit infection except under circumstances in which they 
are the source of a large exposure, such as a blood transfusion 
(8,73). Persons who are HBsAg-negative and anti-HBc-positive 
can experience reactivation of infection during chemotherapy 
or immunosuppressive therapy, with reappearance of HBsAg 
(49). Infection with a mutant HBV strain can result in positive 
laboratory tests for HBsAg, total anti-HBc, anti-HBs, and 
HBV DNA, with a negative IgM anti-HBc.
Perinatal HBV infection in a child aged ≤24 months is 
typically asymptomatic although fulminant hepatitis can occur; 
a positive HBsAg test, positive HBeAg test, or detectable HBV 
DNA may be considered laboratory evidence of perinatal HBV 
in an infant born to an HBV-infected mother if timing criteria 
are met (74). Infants who are born to HBsAg-positive mothers 
and who do not become infected might have detectable 
anti-HBc for up to 24 months after birth from passively 
acquired maternal antibody (7).
Adults at Risk for HBV Infection
In 2015, CDC received 3,370 surveillance case-reports 
of acute HBV infection. Of 2,207 case-reports with risk 
information, 1,151 (52.2%) indicated no risk for HBV 
during the 6 weeks to 6 months prior to illness onset, and the 
remainder indicated at least one risk factor. Injection-drug use 
and multiple sex partners were the most common reported 
sources of HBV transmission (4).
Injection-drug use. Injection-drug use was reported by 
30.3% of 1,657 new reported HBV cases that included 
information about injection-drug use (4). Since 2009, there has 
been an increase in acute HBV infection among non-Hispanic 
whites aged 30–39 years residing in nonurban areas reporting 
injection-drug use as a risk factor (16). Chronic HBV infection 
has been identified in 3.5%-20.0% (midpoint estimate 11.8%) 
of persons who inject drugs (PWID) in a variety of settings 
(75) and 22.6% of PWID have evidence of past infection 
(75). The proportion of HBV cases reporting injection-drug 
use in three states (Kentucky, Tennessee, and West Virginia) 
increased significantly, from 53% during 2006–2009 to 75% 
during 2010–2013 (p<0.001, chi-square) (16).
Sexual (heterosexual and MSM) exposure. Among persons 
with case-reports of HBV infection with information about 
sexual exposure, 26.4% reported having two or more sexual 
partners, 3.3% reported sexual contact with an HBV-infected 
person, and 11.8% of males reported having had sex with 
another male (4). As many as 10%–40% of adults seeking 
treatment in STI clinics have evidence of current or past HBV 
infection. Among adults with acute HBV infection, 39% were 
screened or sought care for an STI prior to becoming infected 
with HBV (76).
Household contacts. An estimated 45% of persons living 
in households with others with chronic HBV infection have 
serologic evidence of past HBV infection, and 16% have 
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evidence of current infection (CDC, unpublished data, 2017). 
Prior to universal infant vaccination, the risk for infection was 
greatest among unvaccinated children living with a person 
with chronic HBV infection in a household or in an extended 
family setting (67,77,78).
Developmentally disabled persons in long-term-care 
facilities. Developmentally disabled persons in residential 
and nonresidential facilities historically have had a chronic 
HBV infection prevalence as high as 20%. The prevalence of 
infection has declined substantially since the implementation 
of routine HepB vaccination in these settings (79–82).
Correctional facilities. The prevalence of chronic HBV 
infection has been higher among prison inmates (1.0%–3.7%) 
than among the general population (83,84), reflecting an 
overrepresentation of persons entering correctional facilities 
with risks for HBV infection (e.g., injection-drug use and 
histories of multiple sex partners).
Persons at risk for occupational exposure to HBV. Before 
HepB vaccination was widely implemented, HBV infection 
was recognized as a common occupational risk among HCP 
(85,86). Routine HepB vaccination of HCP and the use of 
standard precautions have resulted in a 98% decline in HBV 
infections from 1983 through 2010 among HCP (10). The 
Occupational Safety and Health Administration mandates 
that employers offer HepB vaccination to all employees who 
have occupational risk and that postexposure prophylaxis be 
available following an exposure (10,87).
Hemodialysis patients. Since the initiation of HepB 
vaccination and additional infection control precautions for 
hepatitis B in dialysis centers, the incidence of HBV infection 
among hemodialysis patients has declined approximately 95% 
(88,89). Since 1995, the annual incidence has been stable and 
HBsAg seroprevalence has remained at 1% (90). Receipt of 
dialysis was reported in <1% of acute HBV surveillance cases 
with information reported to CDC (4).
Persons with HCV infection. The number of reported 
HCV cases in four Appalachian states (Kentucky, Tennessee, 
Virginia, and West Virginia) increased 364% during 2006–
2012 among persons aged ≤30 years, with injection-drug use 
as the most common reported risk factor (91). The increase 
in HCV infections occurred concomitantly with an increase 
in HBV infections among young adults in rural communities 
in Appalachian states.
Persons with chronic liver disease. Persons with chronic 
liver disease (e.g., cirrhosis, fatty liver disease, alcoholic liver 
disease, and autoimmune hepatitis) are not at increased risk 
for HBV infection unless they have percutaneous or mucosal 
FIGURE 2. Acute hepatitis B virus infection with recovery
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exposure to blood or body fluids. However, concurrent chronic 
HBV infection might increase the risk for progressive chronic 
liver disease in these persons (92).
Travelers to countries where HBV is endemic. Short-
term travelers to countries in which HBV infection is of high 
or intermediate endemicity (Box 3) typically are at risk for 
infection only through exposure to blood in medical or disaster-
relief activities, receipt of medical care that involves parenteral 
exposures, sexual activity, or drug use. Monthly incidence of 
25‒420 per 100,000 travelers has been reported among long-
term travelers to countries where the disease is endemic (93).
Persons with HIV. Approximately 10% of HIV-positive 
persons are coinfected with HBV (94–97). Chronic HBV 
infection has been identified in 6%–14% of HIV-positive 
persons, including in 9%–17% of MSM and in 7%–10% 
of PWID (98). Coinfected persons have increased rates of 
cirrhosis and liver-related mortality (99).
Persons with diabetes. Compared with adults without 
diabetes, adults with diabetes have a 60% higher prevalence 
of past or present HBV infection and twice the odds of 
acquiring acute HBV. Repeated outbreaks of HBV infection 
associated with assisted blood glucose monitoring underscore 
the continued risk for this population (100–102). Data also 
suggest the possibility of a higher case-fatality proportion 
among persons with diabetes acutely infected with HBV 
compared with those without diabetes (9).
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BOX 3. Prevalence of chronic hepatitis B virus infection, by country*
High (≥8% prevalence): Angola, Benin, Burkina Faso, 
Burundi, Cameroon, Central African Republic, Congo, 
Côte d’Ivoire, Djibouti, Equatorial Guinea, Gabon, 
Gambia, Ghana, Guinea, Haiti, Kiribati, Kyrgyzstan, Laos, 
Liberia, Malawi, Mali, Mauritania, Mongolia, Mozambique, 
Namibia, Nauru, Niger, Nigeria, Niue, Papua New Guinea, 
Senegal, Sierra Leone, Solomon Islands, Somalia, South 
Sudan, Sudan, Swaziland, Togo, Tonga, Uganda, Vanuatu, 
Vietnam, Yemen, and Zimbabwe.
Intermediate (5%–7.9% prevalence): Albania, Bhutan, 
Cape Verde, China, Democratic Republic of the 
Congo, Ethiopia, Kazakhstan, Kenya, Marshall Islands, 
Moldova, Oman, Romania, Rwanda, Samoa, South 
Africa, Tajikistan, Tanzania, Thailand, Tunisia, Tuvalu, 
Uzbekistan, and Zambia.
Low Intermediate (2%–4.9% prevalence): Algeria, 
Azerbaijan, Bangladesh, Belarus, Belize, Brunei Darussalam, 
Bulgaria, Cambodia, Colombia, Cyprus, Dominican 
Republic, Ecuador, Eritrea, Federated States of Micronesia, 
Fiji, Georgia, Italy, Jamaica, Kosovo, Libya, Madagascar, 
Myanmar, New Zealand, Pakistan, Palau, Philippines, Peru, 
Russia, Saudi Arabia, Singapore, South Korea, Sri Lanka, 
Suriname, Syria, Tahiti, and Turkey.
Low (≤1.9% prevalence): Afghanistan, Argentina, 
Australia, Austria, Bahrain, Barbados, Belgium, Bolivia, Bosnia 
and Herzegovina, Brazil, Canada, Chile, Costa Rica, Croatia, 
Cuba, Czech Republic, Denmark, Egypt, France, Germany, 
Greece, Guatemala, Hungary, Iceland, India, Indonesia, 
Iran, Iraq, Ireland, Israel, Japan, Jordan, Kuwait, Lebanon, 
Lithuania, Malaysia, Mexico, Morocco, Nepal, Netherlands, 
Nicaragua, Norway, Palestine, Panama, Poland, Portugal, 
Qatar, Serbia, Seychelles, Slovakia, Slovenia, Spain, Sweden, 
Switzerland, Ukraine, UK, United Arab Emirates, United 
States of America, and Venezuela. 
No data: Andorra, Antigua and Barbuda, Armenia, 
The Bahamas, Botswana, Chad, Comoros, Cook Islands, 
Dominica, El Salvador, Finland, Grenada, Guinea- 
Bissau, Guyana, Honduras, Latvia, Lesotho, Lithuania, 
Luxembourg, Macedonia, Maldives, Malta, Mauritius, 
Monaco, Montenegro, North Korea, Paraguay, Saint Kitts 
and Nevis, Saint Lucia, Saint Vincent and the Grenadines, 
San Marino, Sao Tome and Principe, Timor-Leste, Trinidad 
and Tobago, Turkmenistan, and Uruguay.
* Source: CDC. Travelers health: infectious diseases related to travel. Atlanta, GA: US Department of Health and Human Services, CDC; 2017.
Prophylaxis Against HBV Infection
Hepatitis B Vaccines and 
Hepatitis B Immune Globulins
HepB vaccination is the mainstay of HBV prevention 
efforts; HBIG is generally used as an adjunct to HepB vaccine 
in infants born to HBsAg-positive mothers and in certain 
other postexposure prophylaxis situations. The first HepB 
vaccines consisted of plasma-derived HBsAg. Recombinant 
HepB vaccines containing yeast-derived HBsAg purified by 
biochemical and biophysical separation techniques replaced the 
plasma-derived vaccines in the United States by the late 1980s 
(64,103,104). HepB vaccines recommended for use in the 
United States are formulated to contain 10–40 µg of HBsAg 
protein/mL and do not contain thimerosal as a preservative 
(105). HBIG can augment protection until a response to 
vaccination is attained. For those who do not respond to 
HepB vaccination, HBIG administered alone is the primary 
means of protection after an HBV exposure. HBIG provides 
passively acquired anti-HBs and temporary protection (i.e., 
3–6 months). Passively acquired anti-HBs can be detected for 
4–6 months after administration of HBIG (10).
HepB vaccines are available as a single-antigen formulation 
and in combination with other vaccines. The two single-
antigen vaccines recommended for use in the United States, 
Engerix-B (GlaxoSmithKline Biologicals, Rixensart, Belgium) 
and Recombivax HB (Merck & Co., Inc., Whitehouse 
Station, New Jersey), are used for the vaccination of persons 
starting at birth. Of the two combination vaccines, Pediarix 
(GlaxoSmithKline Biologicals, Rixensart, Belgium) is used for 
the vaccination of persons aged 6 weeks–6 years and contains 
recombinant HBsAg, diphtheria and tetanus toxoids and 
acellular pertussis adsorbed, and inactivated poliovirus and 
Twinrix (GlaxoSmithKline Biologicals, Rixensart, Belgium) 
is used for the vaccination of persons aged ≥18 years and 
contains recombinant HBsAg and inactivated hepatitis A virus 
(Table 2). Comvax (Merck & Co., Inc., Whitehouse Station, 
New Jersey), which was used previously for the vaccination of 
persons aged 6 weeks–15 months and contained recombinant 
HBsAg and Haemophilus b conjugate vaccine, has not been 
available for purchase directly from Merck since January 1, 
2015. Discontinuation of Comvax was not related to any 
product safety or manufacturing issues. Aluminum salts 
generally are used as adjuvants to enhance the immune response 
of vaccinated persons.
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TABLE 2. Recommended doses of hepatitis B vaccine, by group and vaccine type
Age group (yrs)
Single-antigen vaccine Combination vaccine
Recombivax Engerix Pediarix* Twinrix†
Dose (µg) Vol (mL) Dose (µg) Vol (mL) Dose (µg) Vol (mL) Dose (µg) Vol (mL)
Birth–10 5 0.5 10 0.5 10* 0.5 N/A N/A
11–15 10§ 1 N/A N/A N/A N/A N/A N/A
11–19 5 0.5 10 0.5 N/A N/A N/A N/A
≥20 10 1 20 1 N/A N/A 20† 1
Hemodialysis patients and other immune-compromised persons
<20 5 0.5 10 0.5 N/A N/A N/A N/A
≥20 40 1 40 2 N/A N/A N/A N/A
Abbreviation: N/A = not applicable.
* Pediarix is approved for use in persons aged 6 weeks through 6 years (prior to the 7th birthday).
† Twinrix is approved for use in persons aged ≥18 years.
§ Adult formulation administered on a 2-dose schedule.
Two HBIG products are licensed for use in the United States: 
HepaGam B (Cangene Corporation, Winnipeg, Canada) 
and Nabi-HB (Biotest Pharmaceuticals Corporation, Boca 
Raton, Florida). HBIG is prepared from the plasma of donors 
with high concentrations of anti-HBs. Source plasma tests 
negative for evidence of HIV, HBV, and HCV. Investigational 
nucleic acid testing for hepatitis A virus and parvovirus B19 
also is performed on pooled samples of source plasma. The 
manufacturing process contains two steps to inactivate viruses 
in the final product: the solvent and detergent step inactivates 
enveloped viruses, and the virus filtration step removes viruses 
based on their size. HBIG products licensed for use in the 
United States contain no preservative and are intended for 
single use only (106).
Vaccine-Induced Seroprotection
The presence of anti-HBs typically indicates immunity 
against HBV infection. Immunocompetent children and adults 
who have vaccine-induced anti-HBs levels of ≥10 mIU/mL 
1–2 months after having received a complete HepB vaccine 
series are considered seroprotected and deemed vaccine 
responders (107). Vaccine-induced seroprotection is considered 
a surrogate of clinical protection. Anti-HBs levels wane 
over time following vaccination related in part to the age at 
vaccination. Approximately 16% of persons vaccinated at age 
<1 year have antibody levels of ≥10 mIU/mL 18 years following 
vaccination, compared with 74% for those vaccinated at 
age ≥1 year (10). However, persons initially responding to 
the full 3-dose HepB vaccine series and who are later found 
to have anti-HBs <10 mIU/mL remain protected. Most 
persons (88%) who receive a challenge dose of HepB vaccine 
30 years after HepB vaccination as children or adults develop 
an antibody response of ≥10 mIU/mL indicating persistent 
immunity to HBV infection (108). Data from this and other 
studies suggests protection against acute symptomatic and 
chronic HBV infection persists for 30 years or more among 
immunocompetent persons who originally responded to HepB 
vaccine (108–110).
The 3-dose HepB vaccine series produces a protective 
antibody response (anti-HBs ≥10 mIU/mL) in approximately 
95% of healthy infants overall (response is lower for infants 
with lower birth weights) (64) and >90% of healthy adults 
aged <40 years (111,112). Among healthy infants, 25% and 
63% achieve anti-HBs levels ≥10 mIU/mL after the first and 
second dose, respectively. Among healthy adults aged <40 years, 
30%–55% and 75% achieve anti-HBs levels ≥10 mIU/mL 
after the first and second dose, respectively (7,8,64). Vaccine 
response is decreased among infants weighing <2000 grams 
and older adults. Other factors (e.g., smoking, obesity, aging, 
chronic medical conditions, drug use, diabetes, male sex, genetic 
factors, and immune suppression) contribute to a decreased 
response to vaccine (113–116). Although immunogenicity is 
lower among immunocompromised persons, those who achieve 
and maintain seroprotective antibody levels before exposure 
to HBV have a high level of protection (8).
Birth dose. A birth dose of HepB vaccine serves as 
postexposure prophylaxis to prevent perinatal HBV infection 
among infants born to HBV-infected mothers. Although 
infants requiring postexposure prophylaxis should be identified 
by maternal HBsAg testing, administration of a birth dose 
to all infants (even without HBIG) serves as a safeguard to 
prevent perinatal transmission among infants born to HBsAg-
positive mothers not identified prenatally because of lack of 
maternal HBsAg testing or failures in reporting test results. 
HepB vaccine or HBIG given alone are 75% and 71% effective 
in preventing perinatal HBV transmission, respectively; their 
combined efficacy is 94% (29,52,117). The birth dose also 
provides protection to infants at risk from household exposure 
after the perinatal period (29,64).
Vaccination produces seroprotection in 98% of healthy 
term infants. Vaccine response is lower among infants with 
birth weights <2000 grams (64). A study among low birth 
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weight infants demonstrated that more infants achieved 
seroprotective anti-HBs levels when vaccine was initiated at 
1 month of age versus within the first 3 days of life (96% vs. 
68%, p<0.02) (118). Vaccine response among infants does 
not vary appreciably by maternal HBsAg status or HBIG 
administration (64).
Adolescents. Approximately 95% of adolescents achieve 
seroprotection following HepB vaccination with a complete 
series (7). The adult (10 µg) dose of Recombivax HB 
administered using a 2-dose compressed schedule at 0 and 
4 months or 0 and 6 months for persons aged 11–15 years 
produces seroprotection proportions nearly equivalent to those 
obtained with the standard regimen of 5 µg administered on 
a 3-dose schedule at 0, 1, and 6 months (99.2% vs. 98.3%) 
(119,120). Data on long-term antibody persistence or 
protection among adolescents for 2-dose schedules are lacking.
Adults. Vaccination with a complete series results in 
seroprotection in >90% of healthy adults aged <40 years. 
Response decreases with age, and seroprotection is achieved 
in 75% of persons aged 60 years (8).
Diabetes. A review of studies assessing HepB vaccine 
response among persons with diabetes mellitus demonstrated 
seroprotection in 93.9% for children with diabetes mellitus 
compared with 100% for children without diabetes mellitus 
(112,121).
Among adults, 88.2% of those with diabetes mellitus, 
compared with 93.6% of those without diabetes mellitus, 
achieved seroprotection (112). Among hemodialysis/chronic 
kidney disease patients, the median proportion protected was 
60.1% for those with diabetes mellitus, compared with 75.1% 
for those without diabetes mellitus (112).
Immunocompromising conditions. The humoral 
response to HepB vaccine is reduced in children and adults 
who are immunocompromised (e.g., hematopoietic stem cell 
transplant recipients, patients undergoing chemotherapy, 
and HIV-infected persons) (122,123). Modified dosing 
regimens, including a doubling of the standard antigen 
dose or administration of additional doses, might increase 
response rates. However, data on response to these alternative 
vaccination schedules are limited (6).
Vaccine Safety
In prelicensure trials, adverse events following HepB 
vaccination were most commonly injection site reactions 
and mild systemic reactions (106). Commonly reported mild 
adverse events from postmarketing data include pain (3%–
29%), erythema (3%), swelling (3%), fever (1%–6%), and 
headache (3%) (124). The estimated incidence of anaphylaxis 
among HepB vaccine recipients is 1.1 per million vaccine doses 
(125). In 2011, the Institute of Medicine concluded that the 
evidence convincingly supports a causal relationship between 
HepB vaccine and anaphylaxis in yeast-sensitive persons, and 
that the evidence is inadequate to accept or reject a causal 
relation between HepB vaccine and several neurologic, chronic, 
and autoimmune diseases (126).
During early postlicensure surveillance, several adverse 
events following HepB vaccination have been described in 
the scientific literature, including Guillain-Barré Syndrome 
(GBS), chronic fatigue syndrome, optic neuritis, multiple 
sclerosis, and diabetes mellitus; however, multiple studies 
have demonstrated no association between receipt of HepB 
vaccine and these conditions (126–129). In addition, no 
evidence of a causal association between rheumatoid arthritis 
(130), Bell’s palsy (131), autoimmune thyroid disease (132), 
hemolytic anemia in children (133), anaphylaxis (134), optic 
neuritis (135), Guillain-Barré Syndrome (136), sudden-onset 
sensorineural hearing loss (137), or other chronic illnesses 
and receipt of HepB vaccine has been demonstrated through 
analysis of VSD data.
During 2005–2015, a total of 20,231 reports of adverse 
events following HepB vaccination among all ages were 
submitted to VAERS. The majority of primary U.S. reports 
(15,787 of 20,231, 78%) were following HepB vaccine 
administered with other vaccines on the same visit. Among 
these, the percentage classified as serious (i.e., if one or more 
of the following is reported: death, life-threatening illness, 
hospitalization or prolongation of existing hospitalization, 
or permanent disability)† was 16.7%, including 402 deaths, 
of which 388 were among infants aged 6 weeks–23 months 
(138). The most frequently reported adverse events for 
vaccines given in combination were fever (23%), injection 
site erythema (11%), and vomiting (10%) (138). Among the 
4,444 single-antigen HepB reports, 6.5% were classified as 
serious, including 43 deaths, of which 27 were among infants 
aged ≤4 weeks. The most frequently reported adverse events 
for single-antigen HepB vaccine were nausea/dizziness (8%) 
and fever/headache (7%).
Vaccination Schedules
Vaccine schedules are determined on the basis of 
immunogenicity data, and, for infants and children, the need 
to integrate HepB vaccine into a harmonized immunization 
schedule (Tables 3 and 4). Primary vaccination generally 
consists of three intramuscular doses administered on a 0-, 
1-, and 6-month schedule (Table 4). Recombivax HB may be 
administered in a 2-dose schedule at 0 and 4–6 months for 
† Code of Federal Regulations. 21 CFR §600.80. Revised April 1, 2010. Available at 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm? fr=600.80.
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TABLE 3. Hepatitis B vaccine schedules for infants, by infant birthweight and maternal HBsAg status
Birthweight Maternal HBsAg status
Single-antigen vaccine Single-antigen + combination vaccine†
Dose Age Dose Age
≥2,000 g Positive 1 Birth (≤12 hrs) 1 Birth (≤12 hrs)
HBIG§ Birth (≤12 hrs) HBIG Birth (≤12 hrs)
2 1–2 mos 2 2 mos
3 6 mos¶ 3 4 mos
4 6 mos¶
Unknown* 1 Birth (≤12 hrs) 1 Birth (≤12 hrs)
2 1–2 mos 2 2 mos
3 6 mos¶ 3 4 mos
4 6 mos¶
Negative 1 Birth (≤24 hrs) 1 Birth (≤24 hrs)
2 1–2 mos 2 2 mos
3 6–18 mos¶ 3 4 mos
4 6 mos¶
<2,000 g Positive 1 Birth (≤12 hrs) 1 Birth (≤12 hrs)
HBIG Birth (≤12 hrs) HBIG Birth (≤12 hrs)
2 1 mos 2 2 mos
3 2–3 mos 3 4 mos
4 6 mos¶ 4 6 mos¶
Unknown 1 Birth (≤12 hrs) 1 Birth (≤12 hrs)
HBIG Birth (≤12 hrs) HBIG Birth (≤12 hrs)
2 1 mos 2 2 mos
3 2–3 mos 3 4 mos
4 6 mos¶ 4 6 mos¶
Negative 1 Hospital discharge or age 1 mo 1 Hospital discharge or age 1 mo
2 2 mos 2 2 mos
3 6–18 mos¶ 3 4 mos
4 6 mos¶
Abbreviations: HBIG = hepatitis B immune globulin; HBsAg = hepatitis B surface antigen.
* Mothers should have blood drawn and tested for HBsAg as soon as possible after admission for delivery; if the mother is found to be HBsAg positive, the infant 
should receive HBIG as soon as possible but no later than age 7 days.
† Pediarix should not be administered before age 6 weeks.
§ HBIG should be administered at a separate anatomical site from vaccine.
¶ The final dose in the vaccine series should not be administered before age 24 weeks (164 days).
persons aged 11–15 years using the adult formulation. Pediarix 
is administered at ages 2, 4, and 6 months; it is not used for 
the birth dose. Twinrix may be administered before travel or 
any other potential exposure on an accelerated schedule at 0, 
7, and 21–30 days, followed by a dose at 12 months. HepB 
vaccination of adult hemodialysis patients consists of high-dose 
(40 µg) Recombivax HB administered on a 0-, 1-, and 6-month 
schedule or high-dose (40 µg) Engerix-B administered on a 
0-, 1-, 2-, and 6-month schedule (106).
Alternative vaccination schedules (e.g., 0, 1, and 4 months 
or 0, 2, and 4 months) have been demonstrated to elicit dose-
specific and final rates of seroprotection similar to those obtained 
on a 0-, 1-, and 6-month schedule. Increasing the interval 
between the first 2 doses has little effect on immunogenicity 
or the final antibody concentration (139–141). The third dose 
confers the maximum level of seroprotection and provides 
long-term protection (142). Longer intervals between the 
last 2 doses (e.g., 11 months) result in higher final antibody 
levels (142) but might increase the risk for acquisition of 
HBV infection among persons who have a delayed response 
to vaccination. Higher geometric mean titers are associated 
with longer persistence of measurable anti-HBs.
Response to Revaccination
A challenge dose of HepB vaccine may be used to determine 
the presence of vaccine-induced immunologic memory 
through generation of an anamnestic response. The term 
“booster dose” has been used to refer to a dose of HepB vaccine 
administered after a primary vaccination series to provide 
rapid protective immunity against significant infection (i.e., 
infection resulting in serologic test results positive for HBV 
and/or clinically significant disease). Among persons who were 
vaccinated prior to age 1 year and found to have anti-HBs levels 
<10 mIU/mL 6–18 years later, a single challenge dose of HepB 
vaccine resulted in anti-HBs levels ≥10 mIU/mL in 60%–97% 
of those tested. Similar results were found among persons 
initially vaccinated at age ≥1 year (10). Immunocompetent 
persons with a response ≥10 mIU/mL following a challenge 
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dose are considered protected, regardless of subsequent declines 
in anti-HBs (10,109).
One study found that of infants born to HBsAg-positive 
women who were not infected at birth and who did not 
respond to a primary vaccine series, all developed seroprotective 
levels of anti-HBs after receipt of 3 additional doses (143). No 
data exist that suggest that children who have no detectable 
antibody after 6 doses of vaccine benefit from additional doses.
Maternal Antiviral Therapy for Preventing 
Perinatal HBV Transmission
Antiviral therapy (i.e., lamivudine, telbivudine, and 
tenofovir) has been studied as an intervention to reduce 
perinatal HBV transmission among pregnant women with 
high HBV DNA levels (e.g., average HBV DNA levels of 
7.6 log10 IU/mL) (144). Maternal antiviral therapy started 
at 28–32 weeks’ gestation, as an adjunct to HepB vaccine and 
HBIG administered to the infant shortly after delivery, has 
been associated with significantly reduced rates of perinatal 
HBV transmission (5). The use of lamivudine and telbivudine 
is limited by viral resistance and mutations. Tenofovir is not 
associated with resistance and is the preferred agent (5). 
Available data support the safety of tenofovir during pregnancy, 
although its use might be associated with reduced bone mineral 
content in infants with in utero exposure (5,39,63,144–146). 
AASLD suggests antiviral therapy to reduce perinatal HBV 
transmission when maternal HBV DNA is >200,000 IU/mL. 
Maternal therapy is generally discontinued at birth to 3 months 
postpartum (5).
Cost-Effectiveness Considerations
HBV prevention strategies targeting perinatal transmission 
are considered very cost-effective (i.e., an incremental 
cost-effectiveness ratio <$25,000). The current strategy of 
administering HepB vaccine and HBIG within 12 hours of 
birth for infants born to HBsAg-positive mothers and universal 
infant vaccination prior to hospital discharge has an incremental 
cost-effectiveness ratio of $6,957 per quality-adjusted life year 
(QALY) saved when compared with a strategy of universal 
infant HepB vaccination prior to hospital discharge alone 
(147). CDC’s U.S. Perinatal Hepatitis B Prevention Program 
(https://www.cdc.gov/hepatitis/partners/perihepbcoord.
htm), which provides case management services to infants 
born to HBsAg-positive women, also has been demonstrated 
to decrease infections, increase QALYs saved, and be a cost-
effective use of resources (148). A strategy of testing HBsAg-
positive pregnant women for HBV DNA, followed by maternal 
antiviral prophylaxis for women with high HBV DNA, would 
TABLE 4. Hepatitis B vaccine schedules for children, adolescents, and adults
Age group
Schedule* (interval represents time 
in months from first dose)
Children (1–10 yrs) 0, 1, and 6 mos
0, 1, 2, and 12 mos
Adolescents (11–19 yrs) 0, 1, and 6 mos
0, 12, and 24 mos
0 and 4–6 mos†
0, 1, 2, and 12 mos
0, 7 days, 21–30 days, 12 mos§
Adults (≥20 yrs) 0, 1, and 6 mos
0, 1, 2, and 12 mos
0, 1, 2, and 6 mos¶
0, 7 days, 21–30 days, 12 mos§
* Refer to package inserts for further information. For all ages, when the HepB 
vaccine schedule is interrupted, the vaccine series does not need to be 
restarted. If the series is interrupted after the first dose, the second dose should 
be administered as soon as possible, and the second and third doses should 
be separated by an interval of at least 8 weeks. If only the third dose has been 
delayed, it should be administered as soon as possible. The final dose of vaccine 
must be administered at least 8 weeks after the second dose and should follow 
the first dose by at least 16 weeks; the minimum interval between the first and 
second doses is 4 weeks. Inadequate doses of hepatitis B vaccine or doses 
received after a shorter-than-recommended dosing interval should be 
readministered, using the correct dosage or schedule. Vaccine doses 
administered ≤4 days before the minimum interval or age are considered valid. 
Because of the unique accelerated schedule for Twinrix, the 4-day guideline 
does not apply to the first three doses of this vaccine when administered on a 
0-day, 7-day, 21–30-day, and 12-month schedule (new recommendation).
† A 2-dose schedule of Recombivax adult formulation (10 µg) is licensed for 
adolescents aged 11–15 years. When scheduled to receive the second dose, 
adolescents aged >15 years should be switched to a 3-dose series, with doses 2 and 
3 consisting of the pediatric formulation administered on an appropriate schedule.
§ Twinrix is approved for use in persons aged ≥18 years and is available on an 
accelerated schedule with doses administered at 0, 7, 21–30 days, and 12 months.
¶ A 4-dose schedule of Engerix administered in two 1 mL doses (40 µg) on a 0-, 
1-, 2-, and 6-month schedule is recommended for adult hemodialysis patients. 
cost an additional $3 million but would save 2,080 QALYs and 
prevent 324 chronic HBV infections, and therefore would be 
considered cost-effective, with an incremental cost-effectiveness 
ratio of $1,583 per QALY saved (36).
Cost-effectiveness also has been assessed for HBV prevention 
strategies outside of the perinatal setting. Vaccinating adults 
aged 20–59 years with diabetes mellitus costs $75,094 per 
QALY saved; cost-effectiveness ratios increase with age at 
vaccination (149). Among previously vaccinated current 
HCP (including those in training), pre-exposure anti-HBs 
testing followed by revaccination and retesting (if necessary, 
based on anti-HBs levels), compared with no intervention, 
was not considered cost-effective with an incremental cost per 
QALY saved of $3–$4 million at year one and approximately 
$800,000 over 10 years (150).
Recommendations
This section contains guidance for the prevention of HBV 
infection, including ACIP recommendations for HepB 
vaccination of infants, children, adolescents, and adults 
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(Box 4) and CDC and ACIP recommendations for HBV 
prophylaxis following occupational and nonoccupational 
exposures, respectively.
Prevention of Perinatal HBV Transmission
Identification and Management of HBV-Infected 
Pregnant Women
• All pregnant women should be tested for HBsAg during 
an early prenatal visit (e.g., first trimester) in each 
pregnancy, even if they have been vaccinated or tested 
previously. Testing those pregnant women known to be 
chronically infected with HBV provides documentation 
of the positive HBsAg test result obtained during 
pregnancy and helps to ensure that their infants will be 
identified for timely prophylaxis.
 – All HBsAg-positive pregnant women should be tested 
for HBV DNA to guide the use of maternal antiviral 
therapy during pregnancy for the prevention of 
perinatal HBV transmission (new recommendation).
 – AASLD suggests maternal antiviral therapy when the 
materna l  HBV DNA i s  >200,000 IU/mL 
(new recommendation).
 – All HBsAg-positive pregnant women should be referred 
to their jurisdiction’s Perinatal Hepatitis B Prevention 
Program (PHBPP) for case management to ensure that 
their infants receive timely prophylaxis and follow-up. 
A copy of the original laboratory report indicating the 
pregnant woman’s HBsAg-positive status should be 
provided to the hospital or birthing facility where the 
delivery is planned and to the HCP who will care for 
the newborn infant.
 – All HBsAg-positive pregnant women should receive 
information concerning HBV that discusses the 
potential use of antiviral therapy, the importance of 
prophylaxis for their infant (HepB vaccine and HBIG 
within 12 hours of birth), completion of the vaccine 
series, and postvaccination serologic testing.
• Women not tested prenatally, those with clinical hepatitis, 
and those whose behaviors place them at high risk for 
HBV infection (e.g., recent or current injection-drug use, 
having had more than one sex partner in the previous 
6 months or an HBsAg-positive sex partner, having been 
evaluated or treated for a STI) should be tested at the time 
of admission to the hospital or birthing facility for delivery.
• All laboratories that provide HBsAg testing of pregnant 
women should use a Food and Drug Administration–
licensed or approved HBsAg test and should perform 
testing according to the manufacturer’s labeling, including 
BOX 4. Persons recommended to receive hepatitis B vaccination
• All infants
• Unvaccinated children aged <19 years
• Persons at risk for infection by sexual exposure
 – Sex partners of hepatitis B surface antigen 
(HBsAg)–positive persons
 – Sexually active persons who are not in a long-term, 
mutually monogamous relationship (e.g., persons 
with more than one sex partner during the previous 
6 months)
 – Persons seeking evaluation or treatment for a 
sexually transmitted infection
 – Men who have sex with men
• Persons at risk for infection by percutaneous or 
mucosal exposure to blood
 – Current or recent injection-drug users
 – Household contacts of HBsAg-positive persons
 – Residents and staff of facilities for developmentally 
disabled persons
 – Health care and public safety personnel with 
reasonably anticipated risk for exposure to blood 
or blood-contaminated body fluids
 – Hemodialysis patients and predialysis, peritoneal 
dialysis, and home dialysis patients
 – Persons with diabetes aged 19–59 years; persons 
with diabetes aged ≥60 years at the discretion of 
the treating clinician
• Others
 – International travelers to countries with high or 
intermediate levels of endemic hepatitis B virus 
(HBV) infection (HBsAg prevalence of ≥2%)
 – Persons with hepatitis C virus infection
 – Persons with chronic liver disease (including, but 
not limited to, persons with cirrhosis, fatty liver 
disease, alcoholic liver disease, autoimmune 
hepatitis, and an alanine aminotransferase [ALT] 
or aspartate aminotransferase [AST] level greater 
than twice the upper limit of normal)
 – Persons with HIV infection
 – Incarcerated persons
 – All other persons seeking protection from HBV 
infection
testing of initially reactive specimens with a licensed 
neutralizing confirmatory test. When pregnant women 
are tested for HBsAg at the time of admission for delivery, 
shortened testing protocols may be used and initially 
reactive results reported to expedite administration of 
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postexposure prophylaxis of infants. Commercial 
laboratories should be encouraged to capture pregnancy 
status for women tested for HBsAg to aid in identification 
of HBV-infected pregnant women.
Management of Infants Born to Women Who Are 
HBsAg-Positive
• All infants born to HBsAg-positive women should receive 
HepB vaccine and HBIG within 12 hours of birth, 
administered at different injection sites (e.g., separate 
limbs). Only single-antigen HepB vaccine should be used 
for the birth dose (Table 3).
• Infants born to women for whom HBsAg testing results 
during pregnancy are not available but other evidence 
suggestive of maternal HBV infection exists (e.g., presence 
of HBV DNA, HBeAg-positive, or mother known to be 
chronically infected with HBV) should be managed as if 
born to an HBsAg-positive mother (new recommendation).
• The HepB vaccine series should be completed according 
to the recommended schedule for infants born to HBsAg-
positive mothers. The final dose in the series should not 
be administered before age 24 weeks (164 days). Although 
not indicated in the manufacturers’ package labeling, 
Pediarix may be used for infants aged ≥6 weeks born to 
HBsAg-positive mothers to complete the vaccine series 
after receipt of a birth dose of single-antigen HepB vaccine 
and HBIG.
• For infants weighing <2,000 grams, the birth dose (i.e., 
the initial HepB vaccine dose) should not be counted as 
part of the vaccine series because of the potentially reduced 
immunogenicity of HepB vaccine in these infants; 3 
additional doses of vaccine (for a total of 4 doses) should 
be administered beginning when the infant reaches age 
1 month. The final dose in the series should not be 
administered before age 24 weeks (164 days).
• Postvaccination serologic testing for anti-HBs and HBsAg 
should be performed after completion of the vaccine series 
at age 9–12 months (generally at the next well-child visit 
following completion of the HepB vaccine series). 
Postvaccination serologic testing should be performed for 
infants born to HBsAg-positive mothers and infants whose 
mother’s HBsAg status remains unknown (i.e., those 
infants who are safely surrendered shortly after birth) (new 
recommendation). Anti-HBs testing should be performed 
using a method that allows detection of the protective 
concentration of anti-HBs (≥10 mIU/mL). Testing should 
not be performed before age nine months to avoid 
detection of passive anti-HBs from HBIG administered 
at birth and to maximize the likelihood of detecting late 
HBV infection. Anti-HBc testing of infants is not 
recommended because passively acquired maternal anti-
HBc might be detected in infants born to HBsAg-positive 
mothers up to age 24 months.
 – HBsAg-negative infants with anti-HBs levels ≥10 mIU/
mL are protected and need no further medical management.
 – HBsAg-negative infants with anti-HBs <10 mIU/mL 
should be revaccinated with a single dose of HepB 
vaccine and receive postvaccination serologic testing 
1–2 months later (new recommendation). Infants 
whose anti-HBs remains <10 mIU/mL following single 
dose revaccination should receive two additional doses 
of HepB vaccine to complete the second series followed 
by postvaccination serologic testing 1–2 months after 
the final dose.
 – Based on clinical circumstances or family preference, 
HBsAg-negative infants with anti-HBs <10 mIU/mL may 
instead be revaccinated with a second, complete 3-dose 
series, followed by postvaccination serologic testing 
performed 1–2 months after the final dose of vaccine.
 – Available data do not suggest a benefit from 
administering additional HepB vaccine doses to infants 
who have not attained anti-HBs ≥10 mIU/mL 
following receipt of two complete HepB vaccine series.
 – HBsAg-positive infants should be referred for 
appropriate follow-up.
• Infants who are born to HBsAg-positive mothers and 
receive postexposure prophylaxis may be breastfed 
beginning immediately after birth.
• For infants transferred to a different facility after birth 
(e.g., hospital with higher level of neonatal care), staff at 
the transferring and receiving facilities should communicate 
regarding the infant’s HepB vaccination and HBIG receipt 
status to ensure prophylaxis is administered in a timely 
manner (new recommendation).
Management of Infants Born to Women with 
Unknown HBsAg Status
• Infants born to women for whom HBsAg testing results 
during pregnancy are not available but other evidence 
suggestive of maternal HBV infection exists (e.g., presence 
of HBV DNA, HBeAg-positive, or mother known to be 
chronically infected with HBV) should be managed as if 
born to an HBsAg-positive mother (new recommendation). 
The infant should receive both HepB vaccine and HBIG 
within 12 hours of birth.
• Women admitted for delivery without documentation of 
HBsAg test results should have blood drawn and tested as 
soon as possible.
• While maternal HBsAg test results are pending, infants 
with birth weights ≥2,000 grams born to women with an 
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unknown HBsAg status should receive the first dose of 
HepB vaccine (without HBIG) within 12 hours of birth. 
Only single-antigen HepB vaccine should be used for the 
birth dose (Table 3).
 – If the mother is determined to be HBsAg-positive, the 
infant should receive HBIG as soon as possible but no 
later than age seven days, and the vaccine series should 
be completed according to the recommended schedule 
for infants born to HBsAg-positive mothers. The final 
dose in the series should not be administered before 
age 24 weeks (164 days). If the mother is determined 
to be HBsAg-negative, the vaccine series should be 
completed according to the recommended schedule for 
infants born to HBsAg-negative mothers. The final 
dose in the series should not be administered before 
age 24 weeks (164 days).
• Because of the potentially decreased immunogenicity of 
vaccine in infants weighing <2,000 grams, these infants 
should receive both single-antigen HepB vaccine and 
HBIG, administered at different injection sites (e.g., 
separate limbs), if the mother’s HBsAg status cannot be 
determined within 12 hours of birth. The birth dose of 
vaccine should not be counted as part of the 3 doses 
required to complete the vaccine series; 3 additional doses 
of vaccine (for a total of 4 doses) should be administered 
according to a recommended schedule on the basis of the 
mother’s HBsAg test result. The final dose in the series 
should not be administered before age 24 weeks (164 days).
 – If it is not possible to determine the mother’s HBsAg 
status (e.g., when a parent or person with lawful custody 
safely surrenders an infant confidentially shortly after 
birth), the vaccine series should be completed according 
to a recommended schedule for infants born to HBsAg-
positive mothers (new recommendation). The final 
dose in the series should not be administered before 
age 24 weeks (164 days). These infants should receive 
postvaccination serologic testing at age 9–12 months, 
and revaccination if necessary (new recommendation).
• Anti-HBs testing should be performed using a method 
that allows detection of the protective concentration of 
anti-HBs (≥10 mIU/mL). Testing should not be performed 
before age nine months to avoid detection of passive anti-
HBs from HBIG administered at birth and to maximize 
the likelihood of detecting late HBV infection. Anti-HBc 
testing of infants is not recommended because passively 
acquired maternal anti-HBc might be detected in infants 
born to HBsAg-positive mothers up to age 24 months.
 – HBsAg-negative infants with anti-HBs levels ≥10 mIU/mL 
are protected and need no further medical management.
 – HBsAg-negative infants with anti-HBs <10 mIU/mL 
should be revaccinated with a single dose of HepB 
vaccine and receive postvaccination serologic testing 
1–2 months later (new recommendation). Infants 
whose anti-HBs remains <10 mIU/mL following single 
dose revaccination should receive two additional doses 
of HepB vaccine to complete the second series, followed 
by postvaccination serologic testing 1–2 months after 
the final dose.
 – Based on clinical circumstances or family preference, 
HBsAg-negative infants with anti-HBs <10 mIU/mL may 
instead be revaccinated with a second, complete 3-dose 
series, followed by postvaccination serologic testing 
performed 1–2 months after the final dose of vaccine.
 – Available data do not suggest a benefit from 
administering additional HepB vaccine doses to infants 
who have not attained anti-HBs ≥10 mIU/mL 
following receipt of two complete HepB vaccine series.
 – HBsAg-positive infants should be referred for 
appropriate follow-up.
• Infants born to mothers with unknown HBsAg status may 
be breastfed beginning immediately after birth.
• For infants transferred to a different facility after birth 
(e.g., a hospital with a higher level of neonatal care), staff 
at the transferring and receiving facilities should 
communicate regarding the infant’s HepB vaccination and 
HBIG receipt status to ensure prophylaxis is administered 
in a timely manner (new recommendation).
Persons Recommended for 
HepB Vaccination
Universal Vaccination of Infants
• All infants should receive the HepB vaccine series as part 
of the recommended childhood immunization schedule, 
beginning at birth as a safety net (Box 4; Table 3).
• For all medically stable infants weighing ≥2,000 grams at 
birth and born to HBsAg-negative mothers, the first dose 
of vaccine should be administered within 24 hours of birth 
(new recommendation). Only single-antigen HepB 
vaccine should be used for the birth dose.
• Infants weighing <2,000 grams and born to HBsAg-
negative mothers should have their first vaccine dose 
delayed to the time of  hospital discharge or age 1 month 
(even if weight is still <2,000 grams). For these infants, a 
copy of the original laboratory report indicating that the 
mother was HBsAg negative during this pregnancy should 
be placed in the infant’s medical record. Infants weighing 
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<2,000 grams at birth have a decreased response to HepB 
vaccine administered before age 1 month (118).
• For infants transferred to a different facility after birth 
(e.g., a hospital with a higher level of neonatal care), staff 
at the transferring and receiving facilities should 
communicate regarding the infant’s HepB vaccination and 
HBIG receipt status to ensure prophylaxis is administered 
in a timely manner (new recommendation).
• The final dose in the vaccine series should not be 
administered before age 24 weeks (164 days).
• In populations with currently or previously high rates of 
childhood HBV infection (e.g., Alaska Natives; Pacific 
Islanders; and immigrant families from Asia, Africa, and 
countries with intermediate or high endemic rates of 
infection), the first dose of HepB vaccine should be 
administered at birth and the final dose at age 6–12 months.
Vaccination of Children and Adolescents
• HepB vaccination is recommended for all unvaccinated 
children and adolescents aged <19 years (Box 4).
• Children and adolescents who have not previously received 
HepB vaccine should be vaccinated routinely at any age 
(i.e., children and adolescents are recommended for 
catch-up vaccination) (Table 4).
Vaccination of Adults
• HepB vaccination is recommended for all unvaccinated 
adults at risk for HBV infection and for all adults requesting 
protection from HBV infection. Acknowledgement of a 
specific risk factor should not be a requirement for 
vaccination (Box 4).
• Adults recommended to receive HepB vaccine:
 – Persons at risk for infection by sexual exposure (e.g., 
sex partners of HBsAg-positive persons, sexually active 
persons who are not in a mutually monogamous 
relationship [e.g., persons with more than one sex 
partner during the previous 6 months], persons seeking 
evaluation or treatment for a sexually transmitted 
infection, and MSM).
 – Persons with a history of current or recent injection-
drug use are at increased risk for HBV infection. An 
increased incidence of HBV incidence among young 
adults in rural U.S. communities has been associated 
with an increase in injection-drug use.
 – Other persons at risk for infection by percutaneous or 
mucosal exposure to blood (household contacts of 
HBsAg-positive persons; residents and staff of facilities 
for developmentally disabled persons; health care and 
public safety personnel with reasonably anticipated risk 
for exposure to blood or blood-contaminated body 
fluids; hemodialysis patients and predialysis, peritoneal 
dialysis, and home dialysis patients; persons with 
diabetes mellitus aged <60 years and persons with 
diabetes mellitus aged ≥60 years at the discretion of the 
treating clinician).
 – Others (international travelers to countries with high 
or intermediate levels [HBsAg prevalence of ≥2%] 
[Box 3] of endemic HBV infection, persons with HCV 
infection, persons with chronic liver disease [including, 
but not limited to, those with cirrhosis, fatty liver 
disease, alcoholic liver disease, autoimmune hepatitis, 
and an ALT or AST level greater than twice the upper 
limit of normal] [new recommendation], persons with 
HIV infection, incarcerated persons, all other persons 
seeking protection from HBV infection without 
acknowledgement of a specific risk factor).
Vaccination of Pregnant Women
• Pregnant women who are identified as being at risk for 
HBV infection during pregnancy (e.g., having more than 
one sex partner during the previous 6 months, been 
evaluated or treated for an STI, recent or current injection-
drug use, or having had an HBsAg-positive sex partner) 
should be vaccinated.
• Pregnant women at risk for HBV infection during 
pregnancy should be counseled concerning other methods 
to prevent HBV infection.
Implementation Strategies
Delivery Hospital Policies and Procedures
• All delivery hospitals and birthing facilities should implement 
policies and procedures to ensure identification of infants 
born to HBsAg-positive mothers and infants born to mothers 
with unknown HBsAg status, initiation of prophylaxis for 
these infants, and routine birth dose for medically stable 
infants weighing ≥2,000 grams within 24 hours of birth. Such 
policies and procedures should include standing orders and 
electronic medical record reminders or prompts.
Case-Management Programs to Prevent Perinatal 
HBV Infection
• States and localities should establish case-management 
programs, including appropriate policies, procedures, laws, 
and regulations to ensure that all pregnant women are 
tested for HBsAg during each pregnancy, and that those 
who are HBsAg-positive are tested for HBV DNA to guide 
maternal antiviral therapy. Infants born to HBsAg-positive 
women and women with unknown HBsAg status also 
should receive case management.
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Settings Providing Services to Adults
• In settings in which a high proportion of persons have risk 
factors for HBV infection (e.g., health care settings 
targeting services to injection-drug users, correctional 
facilities, institutions and nonresidential day care facilities 
for developmentally disabled persons), all adults should 
be assumed to be at risk for HBV infection and should be 
offered HepB vaccination if they have not previously 
completed vaccination.
• HCP should implement standing orders to administer 
HepB vaccine as part of routine services to adults who 
have not completed the vaccine series and make HepB 
vaccination a standard component of evaluation and 
treatment for STIs and HIV/AIDS.
• When feasible, HepB vaccination should be offered in 
outreach and other settings in which services are provided 
to persons at risk for HBV infection (e.g., needle-exchange 
programs, HIV testing sites, HIV prevention programs, 
and homeless shelters).
• In medical settings, HCP should implement standing orders 
to identify adults recommended for HepB vaccination and 
administer vaccination as part of routine services.
Postexposure Prophylaxis
This section provides recommendations for management 
of persons who are exposed to HBV through a distinct, 
identifiable exposure to blood or body fluids that contain 
blood, in occupational and nonoccupational settings.
• Wounds and skin sites that have been in contact with blood 
or body fluids should be washed with soap and water; mucous 
membranes should be flushed with water. Using antiseptics 
(e.g., 2%–4% chlorhexidine) for wound care or expressing 
fluid by squeezing the wound further have not been shown 
to reduce the risk for HBV transmission; however, the use of 
antiseptics is not contraindicated. The application of caustic 
agents (e.g., bleach) or the injection of antiseptics or 
disinfectants into the wound is not recommended.
Occupational Settings
Vaccinated HCP
• For vaccinated HCP (who have written documentation 
of a complete HepB vaccine series) with subsequent 
documented anti-HBs ≥10 mIU/mL, testing the source 
patient for HBsAg is unnecessary. No postexposure 
prophylaxis for HBV is necessary, regardless of the source 
patient’s HBsAg status (Table 5).
• For vaccinated HCP (who have written documentation 
of a complete HepB vaccine series) without previous anti-
HBs testing, the HCP should be tested for anti-HBs and 
the source patient (if known) should be tested for HBsAg 
as soon as possible after the exposure. Anti-HBs testing 
should be performed using a method that allows detection 
of the protective concentration of anti-HBs (≥10 mIU/mL). 
Testing the source patient and the HCP should occur 
simultaneously; testing the source patient should not be 
delayed while waiting for the HCP anti-HBs test results, 
and likewise, testing the HCP should not be delayed while 
waiting for the source patient’s HBsAg results (Table 5).
 – If the HCP has anti-HBs <10 mIU/mL and the source 
patient is HBsAg-positive or has an unknown HBsAg 
status, the HCP should receive 1 dose of HBIG and 
be revaccinated as soon as possible after the exposure. 
HepB vaccine may be administered simultaneously 
with HBIG at a separate anatomical injection site (e.g., 
separate limb). The HCP should then receive the 
second 2 doses of HepB vaccine to complete the second 
series (likely 6 doses total when accounting for the 
original series) according to the vaccination schedule. 
So the HCP’s vaccine response status can be documented 
TABLE 5. Postexposure management of health care personnel after occupational percutaneous or mucosal exposure to blood or body fluids, 
by health care personnel HepB vaccination and response status
HCP status
Postexposure testing Postexposure prophylaxis
Postvaccination 
serologic testing
Source patient 
(HBsAg) HCP testing (anti-HBs) HBIG Vaccination
Documented responder after complete series No action needed
Documented nonresponder after two 
complete series
Positive/unknown -* HBIG x2 separated by 
1 month
- N/A
Negative No action needed
Response unknown after complete series Positive/unknown <10 mIU/mL HBIG x1 Initiate revaccination Yes
Negative <10 mIU/mL None Initiate revaccination Yes
Any result ≥10 mIU/mL No action needed
Unvaccinated/incompletely vaccinated or 
vaccine refusers
Positive/unknown - HBIG x1 Complete vaccination Yes
Negative - None Complete vaccination Yes
Abbreviations: anti HBs = antibody to hepatitis B surface antigen; HBIG = hepatitis B immune globulin; HBsAg = hepatitis B surface antigen; HCP = health care 
personnel; N/A = not applicable.
* Not indicated.
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for future exposures, anti-HBs testing should be 
performed 1–2 months after the final vaccine dose.
 – If the HCP has anti-HBs <10 mIU/mL and the source 
patient is HBsAg-negative, the HCP should receive an 
additional single HepB vaccine dose, followed by repeat 
anti-HBs testing 1–2 months later. HCP whose anti-
HBs remains <10 mIU/mL should undergo 
revaccination with two more doses (likely 6 doses total 
when accounting for the original series). So the HCP’s 
vaccine response status can be documented for future 
exposures, anti-HBs testing should be performed 
1–2 months after the final dose of vaccine.
 – If the HCP has anti-HBs ≥10 mIU/mL at the time of 
the exposure, no postexposure HBV management is 
necessary, regardless of the source patient’s HBsAg status.
• For vaccinated HCP with anti-HBs <10 mIU/mL after 
two complete HepB vaccine series, the source patient 
should be tested for HBsAg as soon as possible after the 
exposure. If the source patient is HBsAg-positive or has 
unknown HBsAg status, the HCP should receive 2 doses 
of HBIG (1,10). The first dose should be administered as 
soon as possible after the exposure, and the second dose 
should be administered 1 month later. HepB vaccine is 
not recommended for the exposed HCP who has 
previously completed two HepB vaccine series. If the 
source patient is HBsAg-negative, neither HBIG nor HepB 
vaccine is necessary (Table 5).
Unvaccinated HCP
• For unvaccinated or incompletely vaccinated HCP, the 
source patient should be tested for HBsAg as soon as 
possible after the exposure. Testing unvaccinated or 
incompletely vaccinated HCP for anti-HBs is not 
necessary and is potentially misleading, because anti-HBs 
≥10 mIU/mL as a correlate of vaccine-induced protection 
has only been determined for persons who have completed 
an approved vaccination series (107) (Table 5).
• If the source patient is HBsAg-positive or has an unknown 
HBsAg status, the HCP should receive 1 dose of HBIG 
and 1 dose of HepB vaccine administered as soon as 
possible after the exposure. HepB vaccine may be 
administered simultaneously with HBIG at a separate 
anatomical injection site (e.g., separate limb). The HCP 
should complete the HepB vaccine series according to the 
vaccination schedule. To document the HCP’s vaccine 
response status for future exposures, anti-HBs testing 
should be performed approximately 1–2 months after the 
final vaccine dose. Anti-HBs testing should be performed 
using a method that allows detection of the protective 
concentration of anti-HBs (≥10 mIU/mL). Because 
anti-HBs testing of HCP who received HBIG should be 
performed after anti-HBs from HBIG is no longer 
detectable (6 months after administration), it might be 
necessary to defer anti-HBs testing for a period longer 
than 1–2 months after the last vaccine dose in these 
situations (Table 5).
 – HCP with anti-HBs ≥10 mIU/mL after receipt of the 
primary vaccine series are considered immune. 
Immunocompetent persons have long-term protection 
and do not need further periodic testing to assess anti-
HBs levels.
 – HCP with anti-HBs <10 mIU/mL after receipt of the 
primary series should be revaccinated. For these HCP, 
administration of a second complete series on an 
appropriate schedule, followed by anti-HBs testing 
1–2 months after the final dose, is usually more 
practical than conducting serologic testing after each 
additional dose of vaccine. So the HCP’s vaccine 
response status can be documented for future exposures, 
anti-HBs testing should be performed 1–2 months after 
the final vaccine dose.
• If the source patient is HBsAg-negative, the HCP should 
complete the HepB vaccine series according to the 
vaccination schedule. So the HCP’s vaccine response status 
can be documented for future exposures, anti-HBs testing 
should be performed approximately 1–2 months after the 
final vaccine dose (Table 5).
 – HCP with anti-HBs ≥10 mIU/mL after receipt of the 
primary vaccine series are considered immune. 
Immunocompetent persons have long-term protection 
and do not need further periodic testing to assess anti-
HBs levels.
 – HCP with anti-HBs <10 mIU/mL after receipt of the 
primary series should be revaccinated. For these HCP, 
administration of a second complete series on an 
appropriate schedule, followed by anti-HBs testing 
1–2 months after the final dose, is usually more practical 
than conducting serologic testing after each additional 
dose of vaccine. So the HCP’s vaccine response status 
can be documented for future exposures, anti-HBs 
testing should be performed 1–2 months after the final 
vaccine dose.
Clinical Management of Exposed HCP
• HCP who have anti-HBs <10 mIU/mL (or who are 
unvaccinated or incompletely vaccinated) and sustain an 
exposure to a source patient who is HBsAg-positive or has 
an unknown HBsAg status should undergo baseline testing 
for HBV infection as soon as possible after the exposure, 
and follow-up testing approximately 6 months later. Testing 
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immediately after the exposure should consist of total anti-
HBc, and follow-up testing approximately 6 months later 
should consist of HBsAg and total anti-HBc.
• HCP exposed to a source patient who is HBsAg-positive 
or has an unknown HBsAg status do not need to take 
special precautions to prevent secondary transmission 
during the follow-up period; however, they should refrain 
from donating blood, plasma, organs, tissue, or semen 
(10). The exposed HCP does not need to modify sexual 
practices or refrain from becoming pregnant (10). If an 
exposed HCP is breastfeeding, she does not need to 
discontinue (7,10). No modifications to an exposed HCP’s 
patient-care responsibilities are necessary to prevent 
transmission to patients based solely on exposure to a 
source patient who is HBsAg-positive or has an unknown 
HBsAg status.
Previously Vaccinated HCP
• Providers should only accept written, dated records as 
evidence of HepB vaccination (151).
• An increasing number of HCP have received routine HepB 
vaccination during childhood. No postvaccination 
serologic testing is recommended after routine infant or 
adolescent HepB vaccination. Because vaccine-induced 
anti-HBs wanes over time, testing HCP for anti-HBs years 
after vaccination might not distinguish vaccine 
nonresponders from responders. Pre-exposure assessment 
of current or past anti-HBs results upon hire or 
matriculation, followed by one or more additional doses 
of HepB vaccine for HCP with anti-HBs <10 mIU/mL 
and retesting anti-HBs, if necessary, helps to ensure that 
HCP will be protected if they have an exposure to HBV-
containing blood or body fluids (Box 5; Figure 3).
 – HCP who cannot provide documentation of 3 doses 
of HepB vaccine should be considered unvaccinated 
and should complete the vaccine series. Postvaccination 
serologic testing for anti-HBs is recommended 
1–2 months after the third vaccine dose. HCP who are 
inadvertently tested before receiving 3 documented 
doses of HepB vaccine and have anti-HBs ≥10 mIU/mL 
should not be considered immune because anti-HBs 
≥10 mIU/mL is a known correlate of protection only 
when testing follows a documented 3-dose series. 
Health care facilities are encouraged to try to locate 
vaccine records for HCP and to enter all vaccine doses 
in their state immunization information system.
Nonoccupational Settings
HBsAg-Positive Source
This section provides recommendations for management 
of persons who are exposed to HBV through a distinct, 
identifiable exposure to blood or body fluids that contain 
blood, in nonoccupational settings (Table 6). The exposed 
person does not need to undergo postvaccination serologic 
testing following vaccination based solely on being exposed.
• Exposed persons who have written documentation of a complete 
HepB vaccine series and who did not receive postvaccination 
testing should receive a single dose of HepB vaccine.
• Exposed persons who are in the process of being vaccinated 
but who have not completed the vaccine series should receive 
a dose of HBIG and complete the HepB vaccine series (it 
is not necessary to restart the HepB vaccine series). HepB 
vaccine may be administered simultaneously with HBIG 
at a separate anatomical injection site (e.g., separate limb).
• Exposed unvaccinated persons should receive both HBIG 
and HepB vaccine as soon as possible after exposure 
(preferably within 24 hours). HepB vaccine may be 
administered simultaneously with HBIG at a separate 
anatomical injection site (e.g., separate limbs). Studies are 
limited on the maximum interval after exposure during 
which postexposure prophylaxis is effective, but the 
interval is unlikely to exceed 7 days for percutaneous 
exposure and 14 days for sexual exposures. The HepB 
vaccine series should be completed according to the 
vaccination schedule.
HBsAg-Unknown Source
• Exposed persons with written documentation of a 
complete HepB vaccine series require no further treatment.
• Exposed persons who are in the process of being vaccinated 
but who are not fully vaccinated should complete the 
HepB vaccine series (it is not necessary to restart the 
vaccination series).
• Exposed unvaccinated persons should receive the HepB 
vaccine series with the first dose administered as soon as 
possible after exposure, preferably within 24 hours. Studies 
are limited on the maximum interval after exposure during 
which postexposure prophylaxis is effective, but the interval 
is unlikely to exceed 7 days for percutaneous exposure and 
14 days for sexual exposures. The vaccine series should be 
completed according to the vaccination schedule.
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Immunization Management Issues
Prevaccination Testing
• Vaccination of persons immune to HBV because of current 
or previous infection or HepB vaccination does not 
increase the risk for adverse events (8). However, in 
populations that have high rates of previous HBV 
infection, prevaccination testing might reduce costs by 
avoiding vaccination of persons who are already immune. 
Prevaccination testing consists of testing for HBsAg, anti-
HBs, and anti-HBc. Serologic testing should not be a 
barrier to vaccination of susceptible persons, especially in 
populations that are difficult to access. Testing is not a 
requirement for vaccination, and in settings where testing 
is not feasible, vaccination of recommended persons 
should continue.
• The first dose of HepB vaccine should typically be 
administered immediately after collection of the blood for 
serologic testing. Prevaccination testing is recommended 
for the following persons (Box 6):
 – household, sexual, or needle-sharing contacts of 
HBsAg-positive persons;
 – HIV-positive persons;
 – persons with elevated alanine aminotransferase (ALT)/
aspartate aminotransferase (AST) of unknown etiology;
 – hemodialysis  patients (refer to 2001 CDC 
recommendations [88] for additional information);
 – MSM; and
 – past or current injection-drug users.
Testing for HBV Infection
• Testing for HBV infection (consisting of testing for 
HBsAg, anti-HBs, and anti-HBc) is also recommended 
for the following persons:
 – persons born in countries of high and intermediate 
HBV endemicity (HBsAg prevalence ≥2%);
 – U.S.-born persons not vaccinated as infants whose 
parents were born in countries with high HBV 
endemicity (≥8%);
 – persons needing immunosuppressive therapy, including 
chemotherapy, immunosuppression related to organ 
transplantation, and immunosuppression for 
rheumatologic or gastroenterologic disorders; and
 – donors of blood, plasma, organs, tissues, or semen.
• All pregnant women should be tested for HBsAg 
during each pregnancy. Pregnant women with positive 
HBsAg tests should be tested for HBV DNA.
Postvaccination Serologic Testing
• Serologic testing for immunity is not necessary after 
routine vaccination of infants, children, or adults.
• Testing for anti-HBs after vaccination is recommended 
for the following persons whose subsequent clinical 
management depends on knowledge of their immune 
status (Box 7):
 – infants born to HBsAg-positive women and infants 
born to women whose HBsAg status remains unknown 
BOX 5. Testing anti-HBs for health care personnel (HCP) vaccinated 
in the past
The issue: An increasing number of HCP have received 
routine hepatitis B (HepB) vaccination during childhood. 
No postvaccination serologic testing is recommended after 
routine infant or adolescent HepB vaccination. Because 
vaccine-induced antibody to hepatitis B surface antigen 
(anti-HBs) wanes over time, testing HCP for anti-HBs 
years after vaccination might not distinguish vaccine 
nonresponders from responders.
Guidance for health care institutions: Health 
care institutions may measure anti-HBs upon hire or 
matriculation for HCP who have documentation of a 
complete HepB vaccine series in the past (e.g., as part 
of routine infant or adolescent vaccination). HCP with 
anti-HBs <10 mIU/mL should receive one or more 
additional doses of HepB vaccine and retesting (Figure 3). 
Institutions that decide to not measure anti-HBs upon hire 
or matriculation for HCP who have documentation of a 
complete HepB vaccine series in the past should ensure 
timely assessment and postexposure prophylaxis following 
an exposure (Table 5).
Considerations: The risk for occupational HBV 
infection for vaccinated HCP might be low enough in 
certain settings so that assessment of anti-HBs status 
and appropriate follow-up should be done at the time of 
exposure to potentially infectious blood or body fluids. This 
approach relies on HCP recognizing and reporting blood 
and body fluid exposures and therefore may be applied 
on the basis of documented low risk, implementation, 
and cost considerations. Certain HCP occupations have 
lower risk for occupational blood and body fluid exposures 
(e.g., occupations involving counseling versus performing 
procedures), and nontrainees have lower risks for blood 
and body fluid exposures than trainees. Some settings 
also will have a lower prevalence of HBV infection in the 
patient population served than in other settings, which will 
influence the risk for HCP exposure to HBsAg-positive 
blood and body fluids.
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FIGURE 3. Pre-exposure evaluation for health care personnel previously vaccinated with complete, ≥3-dose HepB vaccine series who have 
not had postvaccination serologic testing* 
Measure antibody to hepatitis B surface antigen (anti-HBs)
anti-HBs 
≥10 mIU/mL
anti-HBs 
<10 mIU/mL
anti-HBs 
<10 mIU/mL
anti-HBs 
≥10 mIU/mL
Administer 1 dose of HepB vaccine,
postvaccination serologic testing
Administer 2 more doses 
of HepB vaccine, 
postvaccination serologic testing
anti-HBs <10 mIU/mL anti-HBs ≥10 mIU/mL
No action for 
hepatitis B prophylaxis
(regardless of source patient 
hepatitis B surface antigen status)
Health care 
personnel need 
to receive
hepatitis B 
evaluation for 
all exposures
Source: Adapted from CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations 
of the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. MMWR 2006;55(No. RR-16).
* Should be performed 1–2 months after the last dose of vaccine using a quantitative method that allows detection of the protective concentration of anti-HBs 
(≥10 mIU/mL) (e.g., enzyme-linked immunosorbent assay [ELISA]).
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TABLE 6. Postexposure management after distinct nonoccupational percutaneous or mucosal exposure to blood or body fluids
Exposure*
Management
Unvaccinated person Previously vaccinated person
HBsAg-positive source HepB vaccine series and HBIG HepB vaccine dose
HBsAg status unknown for source Hep B vaccine series No management
Abbreviations: HepB = hepatitis B; HBsAg = hepatitis B surface antigen; HBIG = hepatitis B immune globulin.
* Exposures include percutaneous (e.g., bite or needlestick) or mucosal exposure to blood or body fluids, sex or needle-sharing contact, or victim of sexual assault/abuse.
(e.g., infants safely surrendered shortly after birth). 
Postvaccination serologic testing should consist of 
testing for anti-HBs and HBsAg;
 – HCP and public safety workers at risk for blood or 
body fluid exposure;
 – hemodialysis patients (and other persons who might 
require outpatient hemodialysis), HIV-infected 
persons, and other immunocompromised persons (e.g., 
hematopoietic stem-cell transplant recipients or persons 
receiving chemotherapy), to determine the need for 
revaccination and the type of follow-up testing; and
 – sex partners of HBsAg-positive persons, to determine 
the need for revaccination and for other methods of 
protection against HBV infection.
• Testing should be performed 1–2 months after 
administration of the final dose of the vaccine series using 
a method that allows determination of a protective 
concentration of anti-HBs (≥10 mIU/mL).
 – Persons found to have anti-HBs concentrations of 
≥10 mIU/mL after the primary vaccine series are 
considered to be immune.
 – Immunocompetent persons have long-term protection and 
do not need further periodic testing to assess anti-HBs levels.
 – Immunocompromised persons might need annual testing 
to assess anti-HBs concentrations (See Revaccination).
 – Persons found to have anti-HBs concentrations of 
<10 mIU/mL after the primary vaccine series should 
be revaccinated. Administration of all doses in the 
second series, on an appropriate schedule, followed by 
anti-HBs testing 1–2 months after the final dose, is 
usually more practical than serologic testing after one 
or more doses of vaccine (except for when revaccinating 
infants born to HBsAg-positive mothers).
 – Persons who do not have a protective concentration of 
anti-HBs after revaccination should be tested for HBsAg.
 – If the HBsAg test result is positive, the person should 
receive appropriate management, and any household, 
sexual, or needle-sharing contacts should be identified and 
vaccinated. Prevaccination testing (consisting of anti-HBc, 
HBsAg, and anti-HBs) to identify infected persons is 
recommended for household, sexual, or needle-sharing 
contacts of HBsAg-positive persons; serologic testing 
should not be a barrier to vaccination, and the first HepB 
vaccine dose should be administered immediately after 
collection of the blood for serologic testing.
 – Persons who test negative for HBsAg should be 
considered susceptible to HBV infection and should 
be counseled about precautions to prevent HBV 
infection and the need to obtain HBIG postexposure 
prophylaxis for any known or likely exposure to an 
HBsAg-positive source (10).
• Testing HCP with documentation of complete HepB 
vaccination for anti-HBs upon hire or matriculation (i.e., 
pre-exposure assessment of prior response to HepB 
vaccination), followed by one or more additional doses of 
HepB vaccine for HCP with anti-HBs <10 mIU/mL, helps 
to ensure that HCP will be protected if they have an 
exposure to HBV-containing blood or body fluids.
• Anti-HBs levels of ≥10 mIU/mL are generally considered 
seroprotective; however, different assays have different 
assay cutoff values based on which reported levels of anti-
HBs might vary depending on the assay used. Refer to the 
package insert of the test for the determination of actual/
correct levels of anti-HBs antibodies.
Revaccination
• Revaccination (i.e., booster dose, challenge dose, or 
revaccination with a complete series) is not generally 
recommended for persons with a normal immune status 
who were vaccinated as infants, children, adolescents, or 
adults. Available data do not suggest a maximum number 
of booster doses. Revaccination when anti-HBs is 
<10 mIU/mL is recommended for the following persons:
 – Infants born to HBsAg-positive mothers. HBsAg-
negative infants with anti-HBs <10 mIU/mL should 
be revaccinated with a single dose of HepB vaccine, 
and retested 1–2 months later. Infants whose anti-HBs 
remains <10 mIU/mL following single dose 
revaccination should receive two additional doses of 
HepB vaccine on a vaccine schedule to complete the 
second series, followed by anti-HBs testing 1–2 months 
later. Alternatively, these infants may be revaccinated 
with a second 3-dose series and retested (HBsAg and 
anti-HBs) 1–2 months after the final dose of vaccine.
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BOX 6. Persons recommended to receive serologic testing prior 
to vaccination*
• Household, sexual, or needle contacts of hepatitis B 
surface antigen (HBsAg)–positive persons†
• HIV-positive persons†
• Persons with elevated alanine aminotransferase/
aspartate aminotransferase of unknown etiology†
• Hemodialysis patients†
• Men who have sex with men†
• Past or current persons who inject drugs†
• Persons born in countries of high and intermediate 
hepatitis B virus (HBV) endemicity (HBsAg 
prevalence ≥2%)
• U.S.-born persons not vaccinated as infants whose 
parents were born in countries with high HBV 
endemicity (≥8%)
• Persons needing immunosuppressive therapy, 
including chemotherapy, immunosuppression related 
to organ transplantation, and immunosuppression for 
rheumatologic or gastroenterologic disorders
• Donors of blood, plasma, organs, tissues, or semen
* Serologic testing comprises testing for hepatitis B surface antigen (HBsAg), 
antibody to HBsAg, and antibody to hepatitis B core antigen.
† Denotes persons also recommended for hepatitis B vaccination. Serologic 
testing should occur prior to vaccination. Serologic testing should not be a 
barrier to vaccination of susceptible persons. The first dose of vaccine should 
typically be administered immediately after collection of the blood for 
serologic testing.
 – HCP. Completely vaccinated HCP with anti-HBs 
<10 mIU/mL should receive an additional dose of HepB 
vaccine, followed by anti-HBs testing 1–2 months later. 
HCP whose anti-HBs remains <10 mIU/mL should 
complete the second series (usually 6 doses total), followed 
by repeat anti-HBs testing 1–2 months after the final dose. 
Alternatively, it might be more practical for very recently 
vaccinated HCP with anti-HBs <10 mIU/mL to receive 
the second complete series (usually 6 doses total), followed 
by anti-HBs testing 1–2 months after the final dose.
 – Hemodialysis patients. For hemodialysis patients 
treated in outpatient centers, the need for booster doses 
should be assessed by annual anti-HBs testing. A 
booster dose should be administered when anti-HBs 
levels decline to <10 mIU/mL. Anti-HBs testing 
1–2 months following the booster dose to assess 
response is not recommended.
 – Other immunocompromised persons. For other 
immunocompromised persons (e.g., HIV-infected 
persons, hematopoietic stem-cell transplant recipients, and 
persons receiving chemotherapy), the need for booster 
doses has not been determined. Annual anti-HBs testing 
and booster doses should be considered for persons with 
an ongoing risk for exposure.
Interrupted Schedules and Minimum  
Dosing Intervals
• For all ages, when the HepB vaccine schedule is 
interrupted, the vaccine series does not need to be 
restarted. If the series is interrupted after the first dose, 
the second dose should be administered as soon as possible, 
and the second and third doses should be separated by an 
interval of at least 8 weeks. If only the third dose has been 
delayed, it should be administered as soon as possible. The 
final dose of vaccine must be administered at least 8 weeks 
after the second dose and should follow the first dose by 
at least 16 weeks; the minimum interval between the first 
and second doses is 4 weeks. Inadequate doses of 
HepB vaccine or doses received after a shorter-than-
recommended dosing interval should be readministered, 
using the correct dosage or schedule.
• Vaccine doses administered ≤4 days before the minimum 
interval or age are considered valid. Because of the unique 
accelerated schedule for Twinrix, the 4-day guideline does 
not apply to the first 3 doses of this vaccine when 
administered on a 0-day, 7-day, 21–30-day, and 12-month 
schedule (new recommendation).
• In infants, administration of the final dose is not 
recommended before age 24 weeks.
Other Immunization Management Issues
• No differences in immunogenicity have been observed 
when one or 2 doses of HepB vaccine produced by one 
manufacturer are followed by doses from a different 
manufacturer (8). Whenever feasible, the same vaccine 
should be used for the subsequent doses; however, if a 
different brand is administered, the dose should be 
considered valid and does not need to be repeated.
• Providers should only accept dated records as evidence of 
HepB vaccination.
• Although vaccinations should not be postponed if records 
cannot be found, an attempt to locate missing records 
should be made by contacting previous health care 
providers, reviewing state or local immunization 
information systems, and searching for a personally held 
record. If records cannot be located within a reasonable 
time, these persons should be considered susceptible and 
started on the age-appropriate vaccination schedule. An 
anti-HBs ≥10 mIU/mL is a serologic correlate of protection 
only when following a documented, complete series.
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BOX 7. Persons recommended to receive postvaccination serologic 
testing* following a complete series of HepB vaccination
• Infants born to hepatitis B surface antigen (HBsAg)–
positive mothers or mothers whose HBsAg status 
remains unknown (e.g., when a parent or person with 
lawful custody safely surrenders an infant confidentially 
shortly after birth infants safely surrendered at or 
shortly after birth)†
• Health care personnel and public safety workers
• Hemodialysis patients and others who might require 
outpatient hemodialysis (e.g., predialysis, peritoneal 
dialysis, and home dialysis)
• HIV-infected persons
• Other immunocompromised persons (e.g., 
hematopoietic stem-cell transplant recipients or 
persons receiving chemotherapy)
• Sex partners of HBsAg-positive persons
* Postvaccination serologic testing for persons other than infants born to 
HBsAg-positive (or HBsAg-unknown) mothers consists of anti-HBs.
† Postvaccination serologic testing for infants born to HBsAg-positive (or 
HBsAg-unknown) mothers consists of anti-HBs and HBsAg. Persons 
with anti-HBs <10 mIU/mL after the primary vaccine series should be 
revaccinated. Infants born to HBsAg-positive mothers or mothers with 
an unknown HBsAg status should be revaccinated with a single dose of 
HepB vaccine and receive postvaccination serologic testing 1–2 months 
later. Infants whose anti-HBs remains <10 mIU/mL following single dose 
revaccination should receive two additional doses of HepB vaccine, 
followed by postvaccination serologic testing 1–2 months after the final 
dose. Based on clinical circumstances or family preference, HBsAg-
negative infants with anti-HBs <10 mIU/mL may instead be revaccinated 
with a second, complete 3-dose series, followed by postvaccination 
serologic testing performed 1–2 months after the final dose of vaccine. 
For others with anti-HBs <10 mIU/mL after the primary series, 
administration of 3 additional HepB vaccine doses on an appropriate 
schedule, followed by anti-HBs testing 1–2 months after the final dose, 
is usually more practical than serologic testing after ≥1 dose of vaccine.
• In all settings, vaccination should be initiated even though 
completion of the series might not be ensured.
• Adverse events occurring after administration of any vaccine 
should be reported to VAERS. Reports should be submitted 
to VAERS online, by facsimile, or by mail. More information 
about VAERS is available by calling 1-800-822-7967 (toll-
free) or online at https://vaers.hhs.gov.
Future Directions
ACIP and CDC will review these recommendations as new 
epidemiology or other information related to HepB vaccines 
(including licensure of additional HepB-containing vaccines), 
HepB vaccine adverse events, and the experience gained in the 
implementation of these recommendations becomes available. 
Revised recommendations will be developed as needed.
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ISSN: 1057-5987 (Print)
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of 
charge in electronic format. To receive an electronic copy each week, visit MMWR’s free subscription page at https://www.cdc.gov/mmwr/mmwrsubscribe.html. 
Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 
202-512-1800.
Readers who have difficulty accessing this PDF file may access the HTML file at https://www.cdc.gov/mmwr/volumes/67/rr/rr6701a1.htm?s_
cid=rr6701a1_w. Address all inquiries about the MMWR Series, including material to be considered for publication, to Executive Editor, MMWR Series, 
Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30329-4027 or to mmwrq@cdc.gov. 
All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations 
or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses 
listed in MMWR were current as of the date of publication.
